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This thesis discusses the effectiveness of house dust mite allergen control in the treatment 
of allergic asthma. Allergic asthma is a major public health problem affecting several 
million people worldwide, and its prevalence continues to increase [1,2]. The progression 
of allergic asthma primarily involves allergic sensitization to house dust mites [3]. 
Common therapies for the treatment of allergic asthma include allergen avoidance or 
tertiary prevention, pharmacotherapy, and immunotherapy [1]. However, the clinical 
effectiveness of avoiding house dust mite allergen exposure is considered a controversial 
subject [4]. Additionally, clinical evidences of the benefits of avoiding pet allergen 
exposure remain elusive [5]. The absence of considerable evidences necessitate an 
explanation, since the allergen avoidance therapy was introduced as the cornerstone of 
allergy treatment [6]. Multiple issues play a complex and interactive role in associating 
clinical outcomes with the control of allergen exposure [7]. Prior to discussing the points 
of the debate on clinical effectiveness of house dust mite allergen avoidance, we first 
introduce the mono-disciplinary topics that are associated with this subject. This 
introduction consecutively describes in brief the problem of allergic asthma, the biology 
of house dust mites, indoor allergen exposure, the environmental control of exposure, 
and the concept of effectiveness assessment using systematic reviews. After discussing 
the debated points on house dust mite allergen avoidance, we present the aim of this 
thesis.
Asthma
Asthma is a chronic inflammatory disorder of the lower conducting airways [8]. The 
airways are hyper-responsive to a variety of triggers, allergens being one of them [8]. The 
inflammation results in respiratory symptoms such as wheezing, cough, shortness of 
breath, and sleep disruption [8]. An exacerbation is an acute situation marked by severe 
shortness of breath, necessitating a temporary increase in pharmacological treatment 
[9]. The Global Initiative for Asthma (GINA) classifies the severity of asthma by the level 
of treatment required to control symptoms and exacerbations [10]. Mild asthma is 
controlled by the use of a low dose inhaled corticosteroids (ICS) (level 1 and 2), whereas 
severe asthma requires a higher dose of ICS, long-acting beta2-agonist, and subsequently, 
a biological add-on treatment [11]. In asthma, a phenotype (a set of observable 
characteristics) refers to a specific subgroup of asthma that requires a treatment different 
from that provided to another subgroup [12]. Asthma phenotypes have been defined in 
relation to clinical characteristics such as early-onset allergic, late-onset eosinophilic, 
exercise-induced, obesity-related, and neutrophilic asthma [12]. Environmental control 
of allergen exposure aims to treat the allergic phenotype of asthma.
IgE-mediated allergy
An allergy is an extreme reaction of the immune system to the introduction of a previously 
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encountered allergen in the human body [13]. In respiratory allergy, the allergen is 
introduced by inhalation, resulting in inflammatory symptoms in the exposed respiratory 
tract. The immune reaction in respiratory allergy is defined as an IgE-mediated reaction 
[14]. In susceptible subjects, introduction of allergens to and uptake by the respiratory 
tract may lead to subsequent uptake by the antigen presenting cells [15]. This is illustrated 
in Figure 1. Subsequently, the interaction with T-helper 2 cells leads to the production 
of IgE antibodies by B-cells [16]. Crosslinking of two IgE molecules bound to mast cells 
by an allergen leads to mediator release while disarming the antigen [17]. While histamine 
is the most important mediator in the acute phase of the allergic reaction, other mediators, 
such as cytokines and chemokines, are responsible for the late or delayed [that is, more 
chronic] phase [14]. The delayed phase is characterised by the activation of eosinophils 
and the involvement of T lymphocytes and Th2 cytokines, which play a crucial role in 
asthma [16]. The multiple mediators that are released by the mast cells activate the process 
of inflammation [14]. House dust mite allergens are a primary causative agent of IgE-
mediated allergy [18]. We proceed to introducing their biology in the next paragraph.
et al26 proposed to use the term “paucisensitization” to describe 2
to 4 sensitizations and “polysensitization” to describe 5 or more
sensitizations. Polysensitization can be categorized into: (1) cross-
reactivity/cross-sensitization, which is the same IgE binding to
several different allergens with common structural features; and (2)
cosensitization, which is the simultaneous presence of different
IgEs that bind to allergens that may not necessarily have common
structural features.27 Important clinical and immunological dif-
ferences exist between patients who are mono- and polysensitized,
which indicates that polysensitization is the expression of a distinct
disease in both children and adults. Persistence of allergic diseases
over time is associated with multimorbidity and/or allergic poly-
sensitization; moreover, polysensitization was shown to be higher
in patients with multimorbidity in comparison with those with a
single allergic disease.15
Some studies in allergic asthma have shown that multi-
morbidities are independent predictors of key asthma out-
comes.28 Therefore, the choice of treatment in patients with
severe asthma should be optimized based on any existing mul-
timorbidities as these may define the asthma phenotype and
FIGURE 1. Immunological mechanisms in IgE-mediated allergic diseases. Th2 cell, T-helper-2 cell.
FIGURE 2. Multimorbidities associated with severe allergic
asthma. ABPA, Allergic bronchopulmonary aspergillosis;
CRSwNP, chronic rhinosinusitis with nasal polyps.
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Figure 1. IgE-mediated allergic reaction.
By M. Humbert et al., CC BY 4.0, https://doi.org/10.1016/j.jaip.2019.02.030
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Biology of house dust mites
House dust mites are small arthropods (<0.5 mm) belonging to the family Pyroglyphidae 
[19]. The species most commonly detected in domestic environments worldwide include 
Dermatophagoides pteronyssinus, Dermatophagoides farinae, Euroglyphus maynei, and 
Blomia tropicalis [20]. House dust mites are primarily found in domestic textiles such as 
mattresses, carpets, upholstery, and soft toys [19]. They are cold-blooded, requiring an 
optimal temperature of 20 to 25 °C for development [21]; beyond this range, their 
development is slower. The optimal temperature range for humans [22] is close to the 
range required for the development of house dust mites. Therefore, the indoor thermal 
climate is not considered a long-term limiting factor for house dust mites. House dust 
mites are rapidly eliminated at higher temperatures, and tolerate a temperature of 60 °C 
only for ten minutes [21]. Conversely, house dust mites can survive in freezing 
temperatures (-20 oC) for 24 hours [21].
House dust mites contain 70 to 75% water in their body [21]. The water that is lost by 
excretion, defecation, secretion, reproduction, and evaporation needs to be replaced 
[23,24], preferably with water from sources other than metabolic water and the water in 
food [23]. When the absolute humidity of the ambient air is above a specific level, the 
water uptake is equal to or greater than the loss of water, and house dust mites can easily 
grow [23]. This specific limiting level is defined for the critical equilibrium activity (CEA) 
[25], and expressed by the relative humidity. When the relative humidity surrounding 
the house dust mite is below the CEA, they suffer dehydration and their survival levels 
reduce [23]. However, their survival is supported by short durations of daily peak 
humidity levels above the CEA [26].
The life cycle of house dust mites consists of six stages (egg, pre-larva, larva, 
protonymph, tritonymph, and adult), spanning approximately 15 days at 35 °C to 122 
days at 16 °C [19]. During the last four stages, there is an active period followed by a 
quiescent period [19]. The quiescent period, represented by the protonymph, can last 
long, allowing a population to resist unfavourable climatic or nutritional conditions for 
several months [20]. Organs for oxygen and carbon dioxide exchange have not been 
detected in house dust mites [23]. There is limited information on their oxygen 
consumption [27], and it is not denoted as a limiting factor.
Amongst the environmental factors, the relative humidity in the niche is considered 
a limiting factor for the long-term control of house dust mite development [19]. In areas 
with a heating season, a combination of environmental means is required to lower the 
relative humidity in the niche [28]. This concurrent approach involves the intervention 
of interacting factors such as indoor heating, thermal insulation, the production of 
humidity, and indoor air ventilation [28].
The faecal pellets of the house dust mite are the most important source of allergens 
[20]. Mite allergens are classified based on their individual allergen components. The 
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group 1, 2, and 23 allergens are immunodominant, displaying the highest levels of 
reactivity in allergenicity assessments [20]. Group 1 and 2 allergens are proteases that 
increase the permeability of the respiratory mucosa [21], thereby inducing allergic 
inflammation with ease.
Indoor allergen exposure
House dust mites produce small spherical faecal pellets with a mean diameter of 22 μm 
(range 10 to 40 μm) [29]. With time, the wrapped faeces partially degrade into smaller 
fragments (diameter>0.5 μm) [30]. House dust mite allergens are released from textiles 
due to human activity [29]. Other indoor allergens amongst others are produced by cats, 
dogs (size<2 μm), and cockroaches (size>10 μm) [29,31,32]. While cat allergens are 
released from their fur, the allergen from dogs is detected in their saliva and urine [33]. 
Cat allergens are also found in buildings without cats, and are possibly introduced from 
the clothes of cat owners [34]. Cockroach allergens are primarily detected in their faecal 
products [32].
Methods have been developed to measure the indoor allergen exposure [35]. In a 
biochemical assay, the allergens bind to an antibody, and are consequently linked to an 
enzyme [36].  The enzyme produces a detectable signal that serves as a measure for the 
antigen concentration [36]. By sampling the house dust from a textile (load) or from the 
indoor air [airborne], the allergen concentration can be assessed. Measurement of the 
airborne allergen concentration requires a sensitive assay as the levels of airborne dust 
are very low [35]. 
Exposure to house dust mite allergen vary based on location and time [20]. Early 
investigations revealed that exposure to airborne allergens is characterised by a peak level 
or emission, followed by the settlement of the allergens [37]. A long-existing paradigm 
states that the contribution of house dust mite allergens to airway diseases is associated 
with the type of bedding used [6]. In a later rostrum, Tovey and Marks [7] advocated 
that this paradigm is considerably simple to account for the significant variation in house 
dust mite aeroallergen exposure. Moreover, in two pilot studies by Tovey et al. [38,39], 
they observed that bedding materials were not the primary source of house dust mite 
aeroallergen exposure. In these two pilots, exposure during (public) transport was the 
most significant [38,39].
Controlling indoor environmental exposure
Environmental sciences provide methods and approaches for describing exposure, and 
strategies and policies for controlling exposure. These strategies and policies can also be 
applied to issues related to house dust mite aeroallergen exposure.
In the environmental domain, engineering sciences describe pollution and noise problems 
in terms of a source, a transmission path, and a receiver [40]. Control measures may 
involve altering any one or all of these elements [40]. In case of house dust mite allergy, 
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we can consider a source (emission of allergen from a textile), a transmission path 
(airborne exposure), and a receiver (inhalation of allergen by the patient) in a chain 
spanning from a humid microenvironment to the appearance asthmatic symptoms 
(Figure 2). 
Multiple environmental strategies for controlling house dust mite allergen exposure 
have been defined in the twentieth century. Total avoidance aims to create an indoor 
environment completely free of living and dead house dust mites as well as their faecal 
products [19]. An alternative for this strategy is to remove patients temporarily to a mite-
free environment, such as in a hospital [41] or to an alpine mite-free environment [42]. 
Source-based approaches result in exposure-based control [43] and concurrent bedroom 
interventions [24]. In exposure-based control, the choice of intervention is based on the 
primary assessment of the actual exposure in the domestic environment [43]. Concurrent 
bedroom interventions are strategies of combining priori defined bedroom barriers [24]. 
Both textile-based strategies employ methods aimed at killing mites (hot washing at 60 
°C and use of tannic acid or biological products for killing mites, such as neem-oil) and 
preventing the release of allergens from the bedding materials (using a mite-impermeable 
cover or removal of upholstery). All of these products have been tested for clinical efficacy 
in randomized trials, in varying combinations [4]. The receiver-based strategy of air 
purification [44] aims at altering the element of the airborne exposure, often by using a 
high-efficiency particulate air (HEPA) filter, with a diameter of 0.3 μm, capturing at least 
85% of airborne particles, including those containing mite allergens. HEPA filters are 
Figure 2. Chain of events leading to dust mite-related asthmatic symptoms starting from a humid indoor environment.
Window condensation: By Daniel Clauzier - Own work, CC BY 3.0, https://commons.wikimedia.org/w/index.
php?curid=4531675
Dust mite: By CSIRO, CC BY 3.0, https://commons.wikimedia.org/w/index.php?curid=35497118
Clock: By R Classen Layouts, iStock license, Stock ID 936433550
Dust mite faeces: By R. Crutcher, http://www.microlabgallery.com, reprinted with permission
Jumping on bed: By Interstid, iStock license, StockID 1176102351
Attack: By Antonio Guillem, iStock license, StockID 1155214538
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usually utilized in ventilation devices, both mobile as well as the mechanical ventilation 
in a home [44]. A specific application involves the purification of air directly above the 
pillow, defined as the nocturnal laminar airflow [45]. Another receiver-based approach 
could be the use of a mouth cap, as studied in the treatment of rhinitis using nasal filters 
[46]. A particular strategy amongst the former is humidity control [47]. This strategy 
aims to control the house dust mite population [47], however not primary eliminating 
the primary allergen exposure. As the faeces of dust mites remain allergenic for years 
[48], in principle, the elimination of house dust mites does not yet support the 
environmental treatment of allergic asthma. Therefore, in tertiary prevention, combining 
humidity control with a textile-based approach should always be considered.
Environmental policies for controlling pollution aim for total elimination if possible. 
The ALARA-principle (As Low As Reasonably Achievable) is commonly used in 
environment management [49]. Neutrality is another policy, similar to that used in the 
global warming agenda [50]. Neutrality aims to bring the current exposure to a standstill. 
The textile-based strategies of exposure-based control and concurrent interventions as 
well as air purification adopt a certain aspects of the ALARA-principle. A sojourn to an 
alpine environment aims for the total avoidance of pollutants.
The environmental control of exposure aims to realize clinical benefits for the patient. 
In the following paragraph, we introduce the concept for the assessment of clinical 
effectiveness at the highest level of evidence.
Evidence-based effectiveness of interventions and Cochrane reviews
Meta-analysis refers to the generation of results from individual studies, gathering robust 
information on the effectiveness with a high power at the highest level of evidence [51]. 
Cochrane reviews are considered the gold standard; they use explicit, systematic methods 
that are selected with an aim of minimizing bias, thereby providing more reliable findings 
from which conclusions can be drawn and decisions can be made [51]. Therefore, 
Cochrane reviews offer a strong starting point for the evidence-based question of the 
effectiveness of environmental interventions, such as house dust mite allergen control. 
Currently, four Cochrane reviews report the effectiveness of environmental means for 
the treatment of allergic asthma. In a review by Campbell et al. [52] the efficacy of using 
feather bedding was investigated. The trials sampled by Campbell did not fulfil the 
inclusion criteria. Gøtzsche and Johansen [4] reviewed the control of house dust mite 
allergen exposure in 55 trials. As stated, they were unable to demonstrate any clinical 
benefit from measures designed to reduce house dust mite allergen exposure. Kilburn et 
al. [5] studied the effectiveness of pet control. In this meta-analysis, the available trials 
were significantly limited for drawing conclusions. Singh et al. [53] provided limited 
evidence on the use of a mechanical ventilation heat recovery system. Overall, at the 
highest level of evidence, the environmental control of indoor allergen exposure as a 
treatment method for asthma cannot be recommended.
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From debate to impasse
Debates are crucial for scientific developments [54]. A scientific debate is a dispute with 
contending knowledge claims, extending over a longer period, and dividing scientific 
groups [55]. In case of the question on allergen avoidance, the first randomized trials 
investigating extensive measures elaborately reported the benefits of treating allergic 
asthma [56]. At the end of the nineties, Gøtzsche [57] published his first meta-analysis 
on house dust mite allergen control and concluded that these methods “seem to be 
ineffective and cannot be recommended”. During those years, the meta-analysis by 
Gøtzsche et al. received multiple comments [58-60]. The majority of comments were 
rejected by Gøtzsche as “none of the correspondents have provided data to the contrary” 
(at the same level of evidence) [61]. New randomized trials were introduced that did not 
alter the conclusions by Gøtzsche et al. [4,57,62]. Therefore, the debate on allergen 
avoidance is characterised by two scientific claims. The claim of no evidence by Gøtzsche 
dates to 1998. After the introduction of Gøtzsche’s meta-analysis in 1998, no new claims 
were introduced at the same level of evidence. Concurrently, allergists in particular still 
believe that environmental means are of importance [63]. The debate on effectiveness of 
house dust mite allergen control reached an impasse.  
Asthmatic patients and avoidance
The impasse on the effectiveness of allergen control is well-reflected in guidelines. The 
Global Initiative for Asthma (GINA) does not recommend allergen avoidance as a general 
therapy in asthma [64]. Particularly, the evidence for single measures is lacking. The 
World Allergy Organization concluded that the “Complete avoidance of offending 
allergens usually leads to an improvement of symptoms” [1]. On the basis of individual 
studies [66-68], the American Academy of Allergy, Asthma, and Immunology 
recommends minimizing the exposure to dust mite allergens in addition to avoiding 
other relevant allergens, to reduce the risk of developing symptoms [69].
The impasse predominantly affects the Dutch patients’ practice. While scientific 
evidence is lacking and environmental means are not reimbursed, Dutch physicians still 
recommend home-related allergen control to the patients. The Lung Foundation 
Netherlands also recommends controlling exposure for patients who tested positive for 
house dust mite allergens (https://www.longfonds.nl/saneren). Dutch respiratory nurses 
are assigned to counsel patients on the treatment of the indoor environment. In the 
Netherlands, total control remains the starting point of such counsel [70]. However, 
long-term total control is barely achievable [56]. Asthmatic patients urge for access to 
updated evidence-based knowledge on possible clinical benefits of environmental means 
as well as means of exploring new environmental strategies.
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Restarting the debate?
The impasse on the effectiveness of house dust mite allergen control is thus far dominated 
by the extensive Cochrane review by Gøtzsche and Johansen [4]. This meta-analysis is 
characterised by the simple linear combination of results from selected trials on avoidance, 
in an apparently fixed-effects model. However, the simple linear combination is 
contrasting to the variability in asthma [8], the significant variation in allergen exposure 
[39], and the complexity of exposure control [24]. A quick look at the data behind the 
meta-analysis by Gøtzsche and Johansen [4] reveals significant issues at times. For 
instance, the treatment group, as reported by Dharmage et al. [71], exhibited a median 
asthma symptom score of zero at baseline. While Burr et al. [72] provided the treated 
patients with only a mattress encasing, the intervention by Rijssenbeek et al. [73] 
(including encasings, hot washing of sheets, and smooth bedroom floors) could be 
considered to have facilitated total avoidance within the bedroom. In terms of avoidance, 
the difference was starkly contrasting.
An inadequately discussed topic is whether the effectiveness of house dust mite 
allergen control varies for different asthmatic patients, or for differences in interventions, 
or differences in their homes. Possibly, results obtained from the investigation of these 
questions could restart the debate.  
Goal
This thesis aims to systematically review whether patients with allergic asthma benefit 
from environmental means of avoidance, with regard to the type of patient and differences 
in exposure, the strategy of the choice, and the types of interventions, with a focus on 
house dust mite-related asthma. Specific topics facilitate the exploration of oxygen content 
as a factor limiting dust mite survival and the description of personalized allergen 
exposure.
To study the influence of the variation in patients, their exposure, and the differences in 
interventions, the following sub-aims were defined: 
1. To update and extend the existing Cochrane review by Gøtzsche and Johansen [4], 
with a focus on baseline asthma outcomes and allergen exposures.
2. To reintroduce previously defined strategies for mite allergen control and discuss 
their importance in the debate on clinical effectiveness, including future investigations.
3. To continue the meta-analysis by Gøtzsche and Johansen [4] by proposing hypotheses 
on the effectiveness of varying bedding interventions limited to mite-impermeable 
covers.
4. To update the existing systematic review by McDonald et al. [44] by reviewing the 
clinical effectiveness of the air purification strategy.
5. To systematically review the relationship between mite allergen exposure and 
altitudinal characteristics in Europe using existing data subsets.
CHAPTER 1
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6. To examine how house dust mite aeroallergen exposure levels have been reported 
historically, and subsequently, investigate the most effective methods of reportage. 
Outline of the thesis
This thesis reports the subject of clinical effectiveness (chapter two to five) and the topic 
of exposure (chapter six and seven). Chapter two details the asthmatic patients and the 
condition of their domestic environment on which the current evidence is based. Baseline 
characteristics from randomized trials are described for the house dust mite allergen load 
from mattresses as well as the most reported asthma outcomes. In chapter three, we 
reintroduce the strategies of house dust mite avoidance. The results by Gøtzsche and 
Johansen [4] are sub-grouped into the specific strategies and discussed. A specific product 
used in house dust mite allergen avoidance is the mite-impermeable cover that is used 
to wrap bedding equipment. In chapter four, we propose hypotheses on the effectiveness 
of using mite-impermeable covers, when executed according to the concurrent bedroom 
interventions, as defined by Colloff [24]. The clinical effectiveness of air purification for 
the treatment of home-related allergic asthma [44] is updated in chapter five. This strategy 
involves the use of HEPA filters in mobile devices as well as the nocturnal laminar airflow 
for the treatment of home-related allergic asthma (house dust mite, dog, cat, and 
cockroach allergies). The last two chapters report the subject of exposure. In chapter six 
the relationship between mite allergen exposure and altitudinal characteristics in Europe 
is studied using a meta-analysis. The environmental characteristics implicate the outdoor 
temperature in January as a substitute for humidity and air pressure, and to study the 
possible influence of the reduced oxygen levels at high altitudes on the survival of house 
dust mites. Chapter seven discusses the description of house dust mite aeroallergen 
measurement results in bedrooms. Fluctuating aeroallergen measurements are commonly 
summarized using the mean. We introduced the peak exposure as an additional 
characteristic for denoting house dust mite aeroallergen exposure. The results presented 
in chapter two to six are summarized and discussed in chapter seven. A summary is also 
presented in Dutch.
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ABSTR ACT
Background
Evidence regarding the clinical effectiveness of mite allergen avoidance for the treatment 
of asthma is lacking. In previous meta-analyses on mite allergen control, the baseline 
data were not discussed in detail. This study updates and extends the existing Cochrane 
review by Gøtzsche and Johansen (Cochrane Database of Systematic Reviews, 2008, Art. 
No: CD001187), with a focus on baseline asthma outcomes and allergen exposures.
Methods
We used the existing trials in the original Cochrane review and included newly published 
studies. The baseline data for the mite allergen load from the mattress, the standardized 
asthma symptom score (ASS), the forced expiratory volume in 1 s percentage of predicted 
(FEV1 %pred.), and the histamine provocative concentration causing a 20% drop in FEV1 
(PC20) were extracted. First, the mean values of the outcomes were calculated. The 
influence of the mite allergen load was examined with a random-effect meta-regression 
using the metafor package in R. 
Results
Forty-five trials were included; 39 trials reported strategies for concurrent bedroom 
interventions, and 6 trails reported strategies for air purification. The mite allergen load 
ranged from 0.44 to 24.83 μg/g dust, with a mean of 9.86 μg/g dust (95% CI 5.66 to 14.05 
μg/g dust, I2 = 99.8%). All health outcomes showed considerable heterogeneity 
(standardized ASS mean: 0.13, 95% CI 0.08 to 0.18, I2 = 99.9%; FEV1 %pred. mean: 85.3%, 
95% CI 80.5 to 90.1%, I2 = 95.8%; PC20 mean: 1.69 mg/mL, 95% CI 0.86 to 2.52 mg/mL, 
I2 = 95.6%). The covariate mite allergen load did not significantly influence health 
outcomes.
Conclusion
This meta-analysis shows that mite avoidance studies are characterized by the inclusion 
of patients with rather mild to moderate asthma and with varying and sometimes 
negligible levels of allergen exposure. Future studies should focus on patients with severe 
asthma and increased levels of allergen exposure.
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INTRODUCTION
House dust mite-allergic asthma is a prevalent disorder of the lower airways that affects 
hundreds of millions of people worldwide [1, 2]. The immediate allergic reaction to mites 
[3] suggests that controlling exposure to the antigen could be an appropriate first-line 
therapy for the treatment of mite-allergic asthma. However, guidelines and reviews 
provide ambiguous recommendations for mite allergen avoidance [4–6], reflecting a lack 
of consensus in this research field. This lack of consensus on the effectiveness of mite 
allergen avoidance is summarized by a Cochrane review [7], which was unable to 
demonstrate any clinical benefit of avoidance measures designed to reduce mite exposure 
in 55 trials. In addition to the substantial meta-analysis by Gøtzsche and Johansen [7], 
several other meta-analyses on mite allergen avoidance for the treatment of asthma report 
varying results for the effectiveness of avoidance [8–11]. The variation in the complex 
interventions as well as the heterogeneity of several study outcomes urges further 
exploration [12, 13].
The baseline data are a not well reported in the meta-analyses on the effectiveness of 
mite allergen control. These baseline characteristics provide attributes for evidence-based 
decision making in the daily practice of clinicians [14]. First, in the case of asthma, 
baseline characteristics are of particular interest because they reflect the level of asthma 
control and the asthma severity of the patient [15]. Studies still highlight the disparities 
between the asthma severity results between clinical trials and those reported from patient 
practice [16]. Treatable traits have been defined in severe asthma patients and may be 
associated with future exacerbation risk [17]. Second, baseline environmental aspects 
can influence the treatability of allergen-induced asthma [18]. Third, baseline 
characteristics provide statistical independence in the asthma outcomes of interest. This 
quantitative factor relates to the possible relationship between exposure and asthma 
outcomes; for example, in the paradigm of the bedding site introduced in the 1990s [19]. 
In such cases, the quantitative evaluation of the clinical effectiveness of the treatment of 
asthma in a meta-analysis differs from that of the traditional two-sample test [20]. These 
aspects demonstrate that baseline characteristics in a meta-analysis are important for the 
interpretation of the study results [21].
This study updates and extends the existing Cochrane review by Gøtzsche and 
Johansen [7], with a focus on baseline asthma outcomes and allergen exposures.
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METHODS
Searches and selections
The starting point for this protocol was the Cochrane review by Gøtzsche and Johansen 
[7]. This meta-analysis includes 55 trials. An updating search was performed in the 
EMBASE, Medline, and Cochrane databases (see Appendix 1). The titles and/or abstracts 
of the retrieved updated studies were screened in Endnote by the first author to identify 
randomized trials that met the inclusion criteria.  Searches and selections were checked 
by a second author (NWJ). We selected all trials by applying the following inclusion 
criteria; where possible, criteria derived from Gøtzsche and Johansen [7] was applied.
•  The study was published in the English language.
•  The study was a peer-review publication with full text (no abstracts).
•  The study was a randomized controlled trial with blinding.
•  The control included a placebo or no treatment (by Gøtzsche and Johansen [7]).
•  The participants were physician-diagnosed with bronchial allergic asthma. These 
included participants who underwent a mite sensitization assessment with either a 
skin test or serum assay for specific IgE antibodies (by Gøtzsche and Johansen [7]). 
The asthma assessment included a history of asthma symptoms and a pulmonary 
function test.
•  The intervention was designed to reduce the exposure to mite antigens in the home 
for the treatment of asthma (mono-trigger therapy by tertiary avoidance). This could 
include one of the following (by Gøtzsche and Johansen [7]):
 a. Chemical (acaricides);
 b.  Physical (mattress covers, vacuum-cleaning, heating, ventilation, freezing, washing, 
air-filtration, and ionisers);
 c. A combination of chemical and physical.
The flow chart of the updating search was made by use of the PRISMA diagram [22].
Data extraction
The data extraction was elaborated by the first author (FvB); the extracted data included 
the study population, the type of intervention and control (the strategy of avoidance 
[13]), the study methodology (randomization and blinding), and outcomes. The outcomes 
included the
main outcomes and the additional outcomes.
Main outcomes
•  Mite allergen load from the mattress (μg/g dust).
•  Asthma symptom score diaries (e.g. ASS/ACQ).
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•  Forced expiratory volume in 1 s percentage of predicted (%) ( FEV1 %pred.)
•   Histamine or methacholine concentration that causes a 20% reduction in the FEV1 
(PC20).
Additional outcomes
•  Medication usage (use of inhaled corticosteroids: yes or no).
•  Type of patient (child or adult).
•  Presence of co-sensitization
Missing data were requested from the study authors. A second author (NWJ) validated 
the selections and the data extraction by the first author. Any ambiguities in the selections 
and the extractions were resolved by discussion.
The mite allergen load in trials was measured by the allergen content, the number of 
mites or the guanine content. A rapid colorimetric test such as the Acarex® test can be 
used to measure the latter. Mite allergen exposure measured by Acarex® or an equivalent 
test was excluded from the analysis; the Acarex® test is poorly correlated with allergen 
content [23]. To estimate the allergen load from the number of mites in mattresses, the 
mean number of mites can be divided by a factor of 50. This ratio is adapted from a 
nonsensitization threshold for allergens and for mites [24]. However, confidence limits 
for this calculation are unknown. We therefore also excluded mite counts. The most 
reliable way to measure the allergen content is with a chemical assay; the Enzyme-Linked 
Immuno Sorbent Assay (ELISA). In an ELISA the house dust mite allergens in the dust 
extract binds to an antibody, and are consequently linked to an enzyme, producing a 
detectable signal correlating to the antigen concentration in the extract [25]. This assay 
has been the most acceptable assay since 1989 [26]. We limited the studies to those 
measuring the mass (μg/g dust) of the mite allergen loads in mattresses with ELISA. Early 
epidemiologic studies defined a threshold level of 10.0 μg mite allergen per gram of dust, 
above which asthmatic patients are in risk of asthma attacks [24]. Confidence boundaries 
were absent, reducing the threshold to a rule of thumb. Since then, there is a lack of papers 
on this threshold level, and thus never updated.
Questionnaires have been developed to measure asthma symptom scores and the 
adequacy of asthma control, regarding shortness of breath, wheeze, woken by asthma, 
severity of asthma in the morning, limiting activities because of asthma, use of a short-
acting bronchodilator [27]. A limitation of the ASSs is that are no validated cut-off points 
indicating severity or level of control. In the validated questionnaire by Juniper, an ACQ 
of 1.50 (maximum 6) relates to inadequately controlled asthma, [28], corresponding to 
a standardized cut-point of 0.25. The FEV1 measures the obstruction in the airways 
during a forced expiratory flower using a spirometer (15). An FEV1 %pred. of 50 to 79% 
refers to moderate airflow obstruction, and < 50% to (very) severe obstruction [29]. 
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In a standardized bronchoprovocation test, the dose histamine or methacholine is 
determined causing a 20% fall in FEV1, PC20 or PD20 [30]. A PC20 < 1 mg/mL is considered 
a severe airway hyper responsiveness, and > 8 mg/mL as being a normal responsiveness 
[31]. 
The analysis was limited to the main health outcomes with the most reported units. 
In the case of the ASS, we a priori standardized (SMN) the mean (MN) score by dividing 
it by the maximum number of the score (MAX). The variance was standardized in the 
same way (SD2 standardized = SD2 extracted/(MAX2 * number of patients)).
Risk of bias assessment
Gøtzsche and Johansen [7] judged the adequacy of the allocation concealment according 
to the Cochrane guidelines [32]. Their assessment was not included in the data synthesis. 
The trials selected for the updated analysis were assessed similarly for the risk of bias by 
the first author (FvB) using the Cochrane checklist [32]. A second author (NWJ) validated 
the assessment by the first author. Any ambiguities in the assessed risk of bias were 
resolved by discussion. We also did not include the assessments in the data synthesis, as 
we did not hypothesize that the risk of bias or the quality of trials would affect the baseline 
characteristics.
Statistical and sensitivity analyses
The effect size was set as the mean for the physiological outcomes. The ASSs were 
standardized. First, the overall effect of the three health outcomes was estimated using 
a random-effects meta-analysis. Additionally, the I2 value was calculated to examine 
heterogeneity in the outcomes. A random-effect meta-regression and subgroups were 
introduced for all medical outcomes showing at least moderate heterogeneity. Covariates 
and subgroups of interest included the mite allergen load from the mattress at baseline 
and possible confounding by the use of inhaled corticosteroids, the type of patient (child/
adult), and the presence of co-sensitization. Random-effects meta-regressions and 
subgroups were tested for a preferred minimum of ten trials (32). Another sensitivity 
analysis yielded the exclusion of possible outliers as well as the results of the updated 
reference search. All calculations were performed with the metafor 2.0.0 package in R 
3.5.3. [33, 34]. The level of significance was set to α = 0.05.
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RESULT S
Selection of references
The selection and inclusion of studies resulted in two groups of publications. The first 
group included the trials from the Gøtzsche and Johansen [7] analysis (fifty-five trials 
published until July 2011 [35–89]). We excluded twelve of these trials for being only 
abstracts, being published in a non-English language, not reporting data on the treatment 
of mite-allergic asthma, or containing non-usable data (outcomes not of prior interest; 
incomplete data) [35–45, 87]. One of the excluded trials was a large trial by Woodcock 
et al. [87], which dominated the meta-analysis by Gøtzsche and Johansen (weight > 40%). 
Woodcock et al. [87] reported incomplete data in the subset of the mite load as well as 
the ASS. Further, the research team did not report the FEV1 or the PC20 data. The 
remaining forty-three trials were included for data extraction. The second group included 
studies identified in our updated search starting in July 2011 (Figure 1). We found a total 
of 942 titles and abstracts. Nine hundred and fifteen titles were excluded for not reporting 
a randomized blinded trial on the effectiveness of tertiary mite allergen avoidance. 
Twenty-eight potentially relevant titles were selected for inclusion [90–117]. Twenty-six 
full-text articles were excluded for not meeting our inclusion criteria (see Appendix 1). 
Two full-text articles were included in the analysis [97, 115]. Finally, forty-five full-text 
articles were included in the analysis.
Description of the included trials
Thirty-nine trials reported avoidance using concurrent bedroom intervention strategies, 
and six trials reported air purification strategies. In twenty-five trials (56%), patients used 
inhaled corticosteroids at baseline. Twenty-one trials reported on the treatment of 
children with allergic asthma, the other twenty-four reported on the treatment of adults; 
some trials included both children and adults. In nineteen trials, co-sensitization at 
baseline was reported. Gøtzsche and Johansen [7] previously reported that eight of the 
included trials had a low risk of bias. Seven trials were judged to have a high risk of bias. 
The bias in the remaining twenty-eight trials was deemed unclear by Gøtzsche and 
Johansen [7]. We judged the trial by El-Ghitany and El-Salam [97] to have an unclear 
risk of bias [no information on concealment was included]. The trial by Murray et al. 
[115] was judged to have a low risk of bias (use of a computerbased minimization 
procedure).
Mean characteristics at baseline
Seventeen of the forty-five trials reported on the mite allergen load from the mattress at 
baseline, as measured by ELISA (mean 9.86 μg/g dust; 95% CI: 5.66 to 14.05 μg/g dust; 
range 0.44 to 24.83 μg/g dust; n = 1066; I2 = 99.8%; Figure 2). The standardized ASSs at 
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baseline were reported in twelve trials with high heterogeneity (standardized symptom 
score = 0.13; 95% CI: 0.08 to 0.18; range: 0.03 to 0.29; n = 703; I2 = 99.9%; Figure 3). 
Sixteen studies reported the outcome FEV1 %pred. by measuring the percentage predicted 
value (FEV1 %pred. = 85.3%; 95% CI: 80.5 to 90.1%; range 68.5 to 102.2%; n = 816; I
2 = 
95.8%; Figure 4).
Fifteen trials reported PC20 values at baseline, expressed as mg/mL. The mean PC20 
was 1.69 mg/mL (95% CI: 0.86 to 2.52 mg/mL; n = 599; I2 = 95.6%, Figure 5).
Figure 1. Flow chart of the updating literature search and selection of studies
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Dependence, subgroups and sensitivity analysis
The covariate mite allergen load at baseline did not significantly influence the health 
outcomes (standardized ASSs: P = 0.13; FEV1 %pred.: P = 0.81; PC20: P = 0.75, see 
Appendix 1). We calculated the FEV1 %pred. in the adult subgroup (FEV1 %pred.; 
adults = 84.2%, 95% CI: 79.2 to 89.2%; 11 trials). All other subgroups included less 
than ten trials. Finally, the random-effects models for the health outcomes were 
unaltered when excluding the updated trials (symptom score 0.12; FEV1 %pred.: 85.4%; 
PC20: 1.69 mg/mL).
DISCUSSION
This study contributes to the existing Cochrane review by Gøtzsche and Johansen [7] by 
generating hypotheses on the characteristics of asthma outcomes according to baseline 
data as well as possible dependencies for asthma outcomes. We observed considerable 
heterogeneity in the mite allergen load in the mattresses (17 trials), the standardized 
ASSs (12 trials), the FEV1 %pred. values (16 trials), and the PC20 values (15 trials). We 
judged the mean mite allergen load from the mattress at baseline to be moderate (9.86 
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Figure 2. Forest plot of the mite allergen load of the mattress at baseline
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μg/g dust). Overall, the standardized ASSs and the percentage predicted FEV1 %pred. 
suggested a mild to moderate disease. The PC20 at baseline predominantly indicated 
moderate to severe airway hyperresponsiveness according to the definition by Cockroft 
[31]. We did not observe a relationship between the mite allergen load from the mattress 
at baseline and health outcomes. The number of trials available did not allow for 
comparisons between the child and adult subgroups, the inhaled corticosteroid use or 
no use subgroups, or the presence or absence of co-sensitization subgroups.
In this study, we observed several factors related to the three attributes of prior interest. 
The first attribute was asthma severity. We observed a mild to moderate magnitude of 
asthma severity at baseline. We were, however, limited in our evaluation of asthma 
severity by the absence of appropriate instruments to assess asthma control [27, 118] and 
the asthma-related quality of life [119]. Compatible with the situation of pharmacological 
treatments [16], it remains unknown whether the results found by Gøtzsche and Johansen 
[7] are generalizable to patients with uncontrolled asthma. In one trial [55], we extracted 
a median symptom score at daytime of zero for the treatment group. Since the score was 
already zero at baseline, it was probably clear that there would be no clinical benefit 
observed in this subset. The asthma outcomes showed more notable levels, such as a 
FEV1 %pred. above 100%, as reported by Carswell et al. [51]. The moderate asthma status 
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Figure 3. Forest plot of the standardized asthma symptom scores at baseline
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at baseline was possibly related to the use of inhaled corticosteroids, as reported in more 
than half of the included trials [56%]. However, the number of trials available did not 
allow for testing this hypothesis.
A second attribute is the magnitude of the exposure at baseline, which relates to the 
environmental treatability. In four of the included trials [51–53, 115], we observed that 
the mean mite allergen load from the mattress at baseline was quite low [range 0.44 to 
1.91 μg/g dust]. Only one of these four trials included an evaluation of the treatability of 
mite allergen exposure at baseline in their methods [52]. Environmentally, whether such 
low values of exposure are considered treatable remains a question. An exposure level of 
0.44 μg/g dust is quite similar to the exposure level observed in the “low-allergen” region 
of Davos in the European Alps (approximately 0.02 to 0.2 μg/g dust; assessed from [120]). 
In addition, Pingitore and Pinter [121] noted that in many trials, there was no success in 
reducing the mite allergen load. Overall, it seems that multiple clinical trials on avoidance 
paid little attention to the environmental issue of the treatability of the exposure.
Furthermore, the attribute of dependence was of interest in this study. None of the 
medical baseline data could be related to mite allergen exposure from the mattress. This 
indicates that from a meta-viewpoint, at baseline, there was no clinical potential for 
reducing the mite allergen load in the bedding.
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As far as we know, this is the first systematic review of baseline characteristics in trials 
on mite allergen avoidance for the treatment of asthma. This study was executed a priori 
to generate hypotheses for a new meta-analysis on the treatment of mite-allergic asthma 
by environmental control. Generating hypotheses to define a protocol for a meta-analysis 
prevents misleading conclusions [32]. We could not generate a hypothesis on a possible 
relationship with asthma outcomes, particularly considering the mite allergen exposure 
covariate. The mite allergen load from the mattress covariate was limited to the data 
obtained from ELISA. This limitation can be considered a rigorous selection factor to 
prevent bias in this covariate of prior interest. It is possible that some of the covariates 
we used were still unrefined. For instance, the covariate co-sensitization was introduced 
as a binary value (presence yes or no); we believe the next step is to introduce the number 
of co-sensitizations as an ordinal covariate.
The main limitation of this study was that we had to exclude the large trial by 
Woodcock et al. [87] because their data was not usable data for the purpose of this study. 
Woodcock et al. did probably not include patients with uncontrolled asthma. Their 
publication included only adult patients with asthma who were undergoing routine 
management with inhaled corticosteroids in primary care. Though not a limitation, 
another large trial also worth noting is the recently published study by Murray et al. [115]. 
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Murray et al. found that only the use of single covers prevented asthma exacerbations in 
the hospital setting. In a post hoc analysis, Murray et al. reported that relatively younger 
children (P = 0.006), those mono-sensitized to mites (P = 0.04), those with severe asthma 
(P = 0.03), and those not exposed to smoking (P = 0.02) explained the reduced number 
of hospital admissions in the 123 participants. No information was presented on the 
selection of significant covariates or on the power of the calculations. Possibly, the results 
by Murray et al. [115] are explained by a more severe asthma status at baseline than those 
in the participants in the trials included by Gøtzsche and Johansen [7].
The baseline characteristics in a meta-analysis have been the subject of methodological 
studies, emphasizing the careful consideration of this topic in the definition of the 
protocol [21, 122]. Advanced statistical methods to evaluate underlying risk have been 
developed for cases in which the baseline characteristics or the severity of the disease 
among the participants varies [123]. The definition of the types of participants is 
considered a key factor in reviews [32]. A positive example of the explicit (a priori) 
consideration of baseline characteristics was demonstrated in the Cochrane review on 
the treatment of asthma by sublingual immunotherapy [124]. In contrast, the current 
meta-analyses on the treatment of asthma using avoidance were commonly characterized 
by no baseline characteristic reporting [7–11]. Gøtzsche and Johansen [7] stated that 
adjusting for baseline differences would risk biasing the review, “since investigators are 
inclined to show baseline differences and adjust for them when this procedure favours 
the experimental treatment”. By limiting their meta-analysis to the changes and final 
values, Gøtzsche and Johansen [7] did not account for the types of participants they 
reviewed. Other Cochrane reviews on the treatment of asthma or rhinitis by mite allergen 
avoidance [125, 126], recognized for their rigorous methodology, do not account for the 
types of participants, as they did not describe their baseline characteristics. This suggests 
that there is room for improvement in the multiple Cochrane reviews and other meta-
analyses on avoidance.
In conclusion, this systematic review demonstrates that many previous mite avoidance 
studies are characterized by the inclusion of patients with rather mild to moderate asthma 
and with varying and sometimes negligible levels of allergen exposure. Most likely, the 
use of asthma medication modified the baseline asthma outcomes in these studies, leaving 
less room to improve. In future studies, we suggest focusing on patients with partially 
controlled or uncontrolled asthma and assessing asthma control with the appropriate 
instruments [27, 118, 119]. Moreover, to test the efficacy of allergen avoidance, sufficient 
mite exposure at baseline should be present. In the absence of an evidence-based 
threshold level, we suggest the provisional use of the formerly defined rule of thumb that 
suggests that 10.0 μg mite allergen per gram of dust is relevant to asthma symptoms [19].
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A B ST R AC T
Asthma affects three hundred million people worldwide. The effectiveness of house dust 
mite allergen control for asthma treatment is debatable. One aspect that has been little 
discussed in existing meta-analyses is the possible role of environmental strategies. Here, 
we reintroduce the previously defined strategies for mite allergen control and discuss 
their importance to the debate on clinical effectiveness. The strategy of concurrent 
bedroom interventions is related to the combined use of a priori defined interventions, 
while the strategy of exposure-based control relates to the treatment of relevant textiles 
after assessing exposure. The air purification strategy aims to purify the human breathing 
zone of airborne allergens. In Western European patient practice, the use of these 
strategies differs. A post hoc study of the dominant Cochrane review by Gøtzsche and 
Johansen (Cochrane Database of Systematic Reviews, 2008, Art. No: CD001187) appears 
to indicate that a majority of the underlying trials reported on the strategy of concurrent 
bedroom interventions, which were mainly executed in a minimal manner. Some trials 
have reported on the air purification strategy and may potentially alter the debate on 
effectiveness. No trial has reported on the strategy of exposure-based control. We 
therefore hypothesize that the absence of evidence for the effectiveness of mite allergen 
control for asthma treatment applies to the strategy of concurrent bedroom interventions. 
The evidence-based effectiveness of the exposure-based control strategy appears to be 
undetermined. The results of our post hoc reanalysis urge that future meta-analyses of 
mite allergen control should a priori define the environmental strategy under study. 
Future trials of mite allergen control are warranted to test the exposure-based strategy 
as well as the sparsely tested strategy of air purification.
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I N T RODU C T ION
Asthma affects hundreds of millions of people worldwide, and its prevalence is still rising 
[1,2]. The role of house dust mite allergy in asthma is evident; however, it is not exclusive 
[3]. Therapies have been developed for the treatment of allergic asthma, including 
avoidance of mite allergen exposure, immunotherapy and pharmacological treatment 
[4]. However, the effectiveness of mite allergen control has become debatable [5], and 
existing guidelines show a lack of consensus on mite allergen control [6-8]. Therefore, 
gaining knowledge of the clinical effectiveness of avoiding allergen exposure should still 
be considered a research priority compared to controlling other types of exposure [9,10].
The debate on the effectiveness of mite allergen control for the treatment of asthma 
has not been characterized by progress. For instance, repeated comments have been made 
on the meta-analysis by Gøtzsche et al. [5,11,12], pointing to the benefits of multiple 
trigger therapy in a large trial [13]. However, these types of comments have previously 
been rejected by Gøtzsche et al. [14], who said: “none of the correspondents have provided 
data (at the same level of evidence) to the contrary”. Nevertheless, investigators [15] 
continue to mention the benefits of trials excluded previously by Gøtzsche and Johansen 
[16]. One novelty seems to be the introduction of a hypothesis by Tovey and Ferro that 
the debate on effectiveness calls for personalized avoidance by a better understanding of 
the nature of allergen exposure [17].
A little-discussed aspect of the question of clinical effectiveness is the role of mite 
allergen control strategies. Strategies have been defined to avoid house dust mite allergen 
exposure (see the section “Strategies for mite allergen control”), including total avoidance 
[18], exposure-based control [19], concurrent bedroom interventions [20], purification 
of the breathing air [21], and a sojourn in a mite-free [alpine] environment [22]. 
Environmentally, the reduction in exposure by different strategies is not necessarily 
equivalent. It remains unclear whether the absence of evidence of the clinical effectiveness 
of mite allergen control relates to any particular strategy. In this review, we reintroduce 
previously defined strategies for mite allergen control and discuss their importance to 
the debate on clinical effectiveness, including future investigations.
STR ATEGIES FOR MITE ALLERGEN C ONTROL
Initial strategies
Among mono- and multi-trigger approaches [23], strategies can be considered to control 
exposure to house dust mites and their allergens. Prior strategies have related to the 
removal of the patient to a mite-free environment. A sojourn in a Swiss alpine mite-free 
environment has been used more than a hundred years and shown to benefit asthmatic 
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patients temporarily [22]. Platts-Mills et al. [24] removed patients for 2 months or more 
to a dust-free hospital environment, resulting in significantly reduced bronchial 
hyperreactivity. These prior strategies were continued by the strategy of total avoidance 
of the home environment of the asthmatic patients. This strategy of total avoidance has 
defined a combination of measures aiming for an indoor environment completely free 
of living and dead house dust mites as well as their faecal products [18,25]. The measures 
developed have included mainly acaricidal products and mite-impermeable covers. 
However, it became clear that the strategy of total avoidance is rarely achievable by 
patients in the long term [26].
Textile-based strategies
Meanwhile, strategies were defined to gain the benefits of rigorous and intensive total 
avoidance using a more efficient approach. Colloff [20] defined a set of a priori defined 
barriers, called integrated avoidance. We redefine this approach as the strategy of 
concurrent bedroom interventions: a combined approach aimed at controlling house 
dust mite exposure by primarily treating the bedroom environment with a priori defined 
barriers. The original strategy comprises a total of seven barriers. In a more recent 
publication, Colloff updated the strategy to nine barriers [27]. The five primary barriers 
consist of (a) fitting of mite-impermeable covers to all bedding; (b) monthly hot 
laundering of the bedding; (c) removal of the bedroom carpet; (d) weekly vacuuming of 
other textiles with a high-efficiency particulate air (HEPA) filter vacuum cleaner; (e) 
removal of upholstered furniture, rugs, mattresses, and bedding to the outside 
environment for 12 hours to dry, heat and/or freeze, followed by vacuuming. An 
alternative is presented if a primary barrier cannot be executed (four alternatives). The 
strategy of concurrent bedroom interventions as positioned by Colloff [20] garnered less 
attention (three citations, Google Scholar, retrieved October 21, 2018). This strategy was 
introduced at the conference Mites, Asthma and Domestic Design II in Sydney.
Around the same period, van Bronswijk [19] introduced the strategy of selective 
avoidance. We redefine this strategy as exposure-based control: a combined approach 
based on the assessment of the actual exposure in the home environment, followed by 
the extermination of mites and removal of all relevant sources of allergenic dust. This 
strategy assumes the existence of a hygienic threshold for allergen exposure above which 
symptoms will develop (2 μg/g dust) [25]. A simplecolorimetric test was introduced in 
patient practice that related the actual exposure in the home environment to the hygienic 
threshold [28]. In the worst case, the exposure-based strategy results in total avoidance 
of the home environment. The strategy of exposure-based control gathered only two 
citations (Google Scholar, retrieved October 22, 2018). We hypothesize that the low 
number of citations is due to the publication of this strategy at a conference (International 
Conference on Insect Pest in the Urban Environment, Cambridge) rather than a peer-
reviewed journal.
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The measures that constitute the textile-based strategies can be differentiated into 
short-term and long-term measures. Short-term measures aim to directly reduce allergen 
exposure, such as the use of chemical products or washing textiles at 60 °C [18]. These 
types of measures must be repeated throughout the year. Long-term measures aim to 
control allergen exposure only after one or more climatic seasons by lowering the relative 
humidity in niches during the heating season (cold climates) or by airing textiles outside 
during the summer (hot climates) [27-29]. Humidity control is an environmental 
intervention aiming to eradicate living mites but not directly the allergenic mite faeces 
[19]. The mite faeces remain allergenic for a very long time [30], thus urging humidity 
control for use in conjunction with co-acting environmental methods [27]. We judge the 
sole intervention of humidity control as a general improvement of indoor air quality 
(fresh air) by reducing indoor humidity levels [31] but not aiming at the primary control 
of mite allergen exposure. In addition to improving the general quality of the indoor air, 
long-term measures are useful for reducing the need to repeat short-term measures with 
high frequency. The reduced need for repeated intensive cleaning of the home makes 
mite allergen control more achievable by patients in the long term.
Breathing-zone-related strategies
While both the concurrent bedroom interventions strategy and the exposure-based 
strategy focus on the elimination of allergen emissions from textiles, the air purification 
strategy aims to purify the human breathing zone of airborne allergens by use of a HEPA 
filter capturing at least 85% of particles with a diameter of 0.3 μm [32]. Particles of larger 
size, such as mite faeces (diameter approximately 10 to 40 μm [33]), are captured at a 
higher percentage. HEPA filters can be used at varying environmental settings, from a 
laminar airflow in the breathing zone during sleep [34] to the use of portable devices in 
the bedroom [35] or an air filtration unit in the living room [36].
Mixed strategies
Finally, we introduce mixed strategies, referring to a combination of strategies that differ 
in aim or therapy, such as combining the effectiveness of steroids, immunotherapy, and 
impermeable covers from different trials in one meta-analysis without subgrouping. We 
consider the mixed strategies somewhat unwieldy. Even if they are clinically effective, 
the results of mixed strategies are less usable or less efficient for patient practice, 
particularly when a strategy is not completely executed. For instance, patient practice 
does not combine a partial impermeable cover with a partial HEPA filter. An exception 
is the case when all data from a study result from concurrent and completely executed 
strategies. Therefore, insight into the effectiveness of a single strategy is relevant for 
evidence-based clinical decision making.
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EVIDENCE SUPPORTING THE STR ATEGIES
List of meta-analyses
In the section above, we reintroduced the environmental strategies for mite allergen 
control. After the introduction of textile-based strategies in the early 1990s, the first 
meta-analysis was performed to assess the effectiveness of mite allergen control at the 
highest level of evidence [5]. This meta-analysis was later continued in a Cochrane review 
[37]. In this meta-analysis, Gøtzsche and Johansen included trials on mite-impermeable 
covers as well as air purification; thus, they investigated a mixture of strategies. The next 
meta-analysis studied the effectiveness of purifying the air using air filtration for the 
treatment of allergic asthma [38]. All treatment groups investigated included the use of 
a HEPA filter, sometimes combined with mite-impermeable covers. The HEPA filters 
were studied in varying environmental settings. Macdonald et al [39] studied the 
effectiveness of textile-based strategies for the primary and tertiary prevention of asthma. 
They reported on the number of days ill due to asthma and a lung function parameter 
combining the FEV1 with the peak flow [39]. Campbell and Gibson attempted to study 
the effects of feather bedding, but the selected trials did not meet the inclusion criteria 
[40]. In another Cochrane review, Singh and Jaiswal [41] studied the effectiveness of 
humidity control for the treatment of asthma. We believe that the environmental strategy 
studied by Singh yields a general improvement of indoor air quality (fresh air) but not 
mite control. Crocker et al. [23] investigated the effectiveness of home-based multi-trigger 
interventions. The meta-analysis by Crocker et al. [23] included a small number of 
patients with house dust mite allergic asthma (34%). Three meta-analyses on the 
effectiveness of concurrent bedroom interventions using mite-impermeable covers were 
introduced in 2014. Arroyave et al. [42] included seven trials on the treatment of asthma. 
In the same year, van Boven [43] generated a hypothesis regarding the effectiveness of 
mite-impermeable covers using a meta-analysis. Van Boven [43] limited the intervention 
to trials that covered all bedding elements (mattress, duvet, and pillow), fitting it to the 
definition of the strategy of concurrent bedroom interventions [27]. Huiyan et al. [44] 
investigated six trials on mite-impermeable covers combined with one trial on humidity 
control. Three of the trials investigated by Huiyan et al. [38-44] were also included in the 
analysis by Gøtzsche and Johansen [37]. To some extent, many meta-analyses can be 
considered to represent subsets of the large meta-analysis by Gøtzsche and Johansen [37].
Clinical effectiveness
Clinical benefits in patients with house dust mite allergy-related asthma were reported 
by small meta-analyses. McDonald et al. [38] reported a significant standardized mean 
difference in the asthma symptom score (95% CI: -0.69 to -0.25; 88 patients) and the 
sleep disturbance (95% CI: -1.44 to -0.42; 47 patients). Macdonald et al. [39] found a 
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positive reduction in the number of days ill (95% CI: –0.59 to –0.13 by two trials). Van 
Boven [43] observed that the more bedroom interventions were combined, the higher 
the reduction in the mite load from the mattress when the load was high at baseline (P 
= 0.02; nine trials). Among the listed meta-analyses, the meta-analysis by Gøtzsche and 
Johansen [37] dominates the debate. While Gøtzsche and Johansen were unable to 
demonstrate any clinical benefit based on 55 trials, Bousquet et al. [45] concluded from 
this meta-analysis that the use of a single intervention measure is not effective. Pingitore 
and Pinter [46] mentioned that Gøtzsche and Johansen included trials reporting no 
reduction in mite allergen exposure. As the meta-analysis by Gøtzsche and Johansen [37] 
reports on a mix of strategies without subgrouping, the role of the specific strategies 
remains unclear.
T H E P O S SI BL E ROL E S OF ST R AT E G I E S I N E F F E C -
T I V E N E S S :  A N E X A M PL E
Methods
The debate on effectiveness is dominated by the large and rigorous meta-analysis by 
Gøtzsche and Johansen [37]. This meta-analysis on a mix of strategies did not subgroup 
for possible differences between mite allergen control strategies. We post hoc subgrouped 
the results by Gøtzsche and Johansen [37] into categories based on the environmental 
strategy used for mite allergen control. The extractions as published by Gøtzsche and 
Johansen [37] were the basis of this reanalysis. Outcomes were limited to the number of 
patients improved, the medication usage, the asthma symptom score, the forced expiratory 
volume in one second (FEV1), and the histamine or methacholine concentration that 
caused a 20% reduction in FEV1 (PC20). The assessment of the type of strategy as studied 
in the underlying trials yielded three judgements:
• Assessing the strategy used to control mite allergen exposure. The strategy 
was defined as "concurrent bedroom interventions" for any a priori defined 
intervention aimed at reducing the mite allergen load while not assessing the 
relevant sites of exposure in the home environment.
• If the intervention was judged to follow the strategy of concurrent bedroom 
interventions, we assessed the number of barriers used.
• If the strategy of concurrent bedroom interventions was not followed 
consequently, the number of barriers was set at one. For instance, the single 
treatment of a carpet in the living room was judged as one barrier (Barrier 4: 
Vacuuming of other textiles).
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Effect sizes were calculated by a random-effects model with the metafor package 2.0.0 
[47] in R (version 3.4.1) [48]. Subgroup analysis yielded a calculation of the effect size 
related to the environmental control strategy. We continued subgrouping the strategy of 
concurrent bedroom interventions to the use of one barrier or two or more barriers. For 
other statistical aspects, we referred to the original study by Gøtzsche and Johansen [37]. 
The level of significance was set to α = 0.05. The magnitude of the standardized mean 
difference (SMD) was judged to be small for an SMD of 0.2, medium for an SMD of 0.5, 
and large for an SMD of 0.8 [49].
Results of the subgrouping analysis
Gøtzsche and Johansen [37] investigated mixed strategies in 55 randomized trials 
(concurrent bedroom interventions, air purification, and combinations). Thirty-six of 
these trials reported on one or more outcomes of interest (Table 1; Ref. 34-36; 50-82). 
Thirty trials tested an intervention based on the strategy of concurrent bedroom 
interventions, of which twenty-three interventions were classified as one barrier (77%). 
Seven trials were classified as investigating two or three barriers (23%). Six trials 
investigated the air purification strategy. No trial reported on an investigation of the 
strategy of exposure-based control. The remaining subgroups that reported on one barrier 
(concurrent bedroom interventions) included a total of 3031 patients (74%), the 
subgroups that reported on two or more barriers included 817 patients (20%), and the 
subgroups that reported on air purification included 258 patients (6%).
The SMD in asthma symptom scores ranged from SMD = -0.03 to -0.53, with all 
P-values ranging from 0.19 to 0.87 (Table 2). Heterogeneity ranged from I2 = 54% to 91%. 
For FEV1, the SMD ranged from +0.07 to +0.17, with P-values ranging from 0.08 to 0.81 
and negligible heterogeneity (I2 = 0 to 28%) (Table 3). Three subgroups reported on PC20 
outcome, with the SMD ranging from -0.12 to +0.05 (P =0.45 to 0.80) (Table 4). The 
subgroups showed no heterogeneity (I2 = 0%). For medication usage, two subgroups 
reported an SMD = -0.04 to -0.17 (P = 0.46 to 0.49; I2 = 0%) (Table 5). The risk ratio for 
the number improved in the subgroups of concurrent bedroom interventions was 0.85 
to 1.07 (P = 0.77 to 0.87), with an absence of heterogeneity (Table 6). In the subgroup of 
air purification, we found a non-significant risk ratio of 0.67 (P = 0.61), with an absence 
of heterogeneity.
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Table 1. Environmental strategy categories of the trials studied by Gøtzsche and Johansen [37]
Trial Author Year Strategy Barriers Remark
1 Antoniceli 1991 Air purification NA
2 Bahir 1997 Concurrent bedroom 1
3 Burr 1980A Concurrent bedroom 1
4 Burr 1980B Concurrent bedroom 1
5 Carswell 1996 Concurrent bedroom 3
6 Chang 1996 Concurrent bedroom 1
7 Chen 1996 Concurrent bedroom 1
8 Cinti 1996 Concurrent bedroom 1 Strategy extracted from description by 
Gøtzsche and Johansen
9 Cloosterman 1999 Concurrent bedroom 2
10 De_Vries 2007 Concurrent bedroom 1
11 Dharmage 2006 Concurrent bedroom 1
12 Dieteman 1993 Concurrent bedroom 1
13 Dorward 1988 Concurrent bedroom 1
14 Ehnert 1992 Concurrent bedroom 2
15 Fang 2001 Concurrent bedroom 1
16 Geller-Bernst 1995 Concurrent bedroom 1
17 Halken 2003 Concurrent bedroom 1
18 Htut 2001 Concurrent bedroom 1
19 Huss 1992 Concurrent bedroom 1
20 Kroidl 1998 Concurrent bedroom 1
21 Maesen 1977 Air purification NA
22 Marks 1994 Concurrent bedroom 2
23 Reiser 1990 Concurrent bedroom 1
24 Rijssenbeek 2002 Concurrent bedroom 3
25 Sette 1994 Concurrent bedroom 1
26 Shapiro 1999 Concurrent bedroom 2
27 Sheikh 2002 Concurrent bedroom 1
28 Thiam 1999 Concurrent bedroom 2
29 Van_der_Heide 1997A Concurrent bedroom 1
30 Verrall 1988 Air purification NA
31 Walshaw 1986 Concurrent bedroom 1
32 Warburton 1994 Air purification NA
33 Warner 1993 Air purification NA
34 Woodcock 2003 Concurrent bedroom 1
35 Wright 2009 Concurrent bedroom 1
36 Zwemer 1973 Air purification NA
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Table 2. Standardized mean differences in asthma symptom scores related to environmental strategy in the meta-analysis by 
Gøtzsche and Johansen [37]
Strategy SMD 95% CI Patients (n) P-value I2
Sojourn high altitude NA NA NA NA NA
Total avoidance NA NA NA NA NA
Exposure-based NA NA NA NA NA
Concurrent bedroom -0.07 -0.35 to 0.21 1415 0.62 68%
   1 barrier -0.03 -0.37 to 0.32 1169 0.87 54%
   2-3 barriers -0.25 -0.89 to 0.40 246 0.43 91%
Air purification -0.53 -1.35 to 0.30 70 0.19 68%
Mixed strategies -0.13 -0.40 to 0.15 1485 0.35 72%
Gøtzsche & Johansen a -0.06 -0.16 to 0.05 1485 0.29 68%
a Standardized mean differences as calculated by Gøtzsche and Johansen [37] with a fixed-effect model.
Table 3. Standardized mean differences in FEV1 related to environmental strategy in the meta-analysis by Gøtzsche and 
Johansen [37]
Strategy SMD 95% CI Patients (n) P-value I2
Sojourn high altitude NA NA NA NA NA
Total avoidance NA NA NA NA NA
Exposure-based NA NA NA NA NA
Concurrent bedroom -0.07 -0.35 to 0.21 1415 0.62 68%
   1 barrier -0.03 -0.37 to 0.32 1169 0.87 54%
   2-3 barriers -0.25 -0.89 to 0.40 246 0.43 91%
Air purification -0.53 -1.35 to 0.30 70 0.19 68%
Mixed strategies -0.13 -0.40 to 0.15 1485 0.35 72%
Gøtzsche & Johansen a -0.06 -0.16 to 0.05 1485 0.29 68%
a Standardized mean differences as calculated by Gøtzsche and Johansen [37] with a fixed-effect model.
Table 4. Standardized mean differences in PC20 related to environmental strategy in the meta-analysis by Gøtzsche and Johansen 
[37]
Strategy SMD 95% CI Patients (n) P-value I2
Sojourn high altitude NA NA NA NA NA
Total avoidance NA NA NA NA NA
Exposure-based NA NA NA NA NA
Concurrent bedroom 0.05 -0.09 to 0.20 475 0.45 0%
   1 barrier 0.05 -0.20 to 0.30 254 0.68 0%
   2-3 barriers 0.05 -0.21 to 0.32 221 0.69 0%
Air purification -0.12 -1.05 to 0.80 18 0.80 0%
Mixed strategies 0.05 -0.13 to 0.22 493 0.61 0%
Gøtzsche & Johansen a 0.05 -0.13 to 0.22 493 0.61 0%
a Standardized mean differences as calculated by Gøtzsche and Johansen [37] with a fixed-effect model.
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Discussion of the subgrouping analysis
Overall, post hoc subgrouping shows that the environmental intervention studied in the 
meta-analysis by Gøtzsche and Johansen [37] relates predominantly to the concurrent 
bedroom interventions strategy and little to the air purification strategy. A majority of 
the underlying trials reported on the strategy of concurrent bedroom interventions with 
one barrier or when performed in an inconsistent manner that was also classified as one 
barrier. When grouping the outcomes of the strategy of concurrent bedroom interventions 
as one barrier or two or more barriers, as well as the strategy of air purification, all effect 
sizes were not significant. The outcome of the asthma symptom score showed a non-
significant increase in the SMD, from zero in the subgroup with one barrier to a small 
effect in the subgroup with two barriers, to a larger effect in the group with air purification. 
Table 5. Standardized mean differences in medication usage related to environmental strategy in the meta-analysis by Gøtzsche 
and Johansen [37]
Strategy SMD 95% CI Patients (n) P-value I2
Sojourn high altitude NA NA NA NA NA
Total avoidance NA NA NA NA NA
Exposure-based NA NA NA NA NA
Concurrent bedroom -0.04 -0.16 to 0.08 1043 0.49 0%
   1 barrier -0.04 -0.16 to 0.08 1043 0.49 0%
   2-3 barriers NA NA NA NA NA
Air purification -0.17 -0.64 to 0.29 72 0.46 0%
Mixed strategies -0.05 -0.17 to 0.07 1115 0.39 0%
Gøtzsche & Johansen a -0.05 -0.17 to 0.07 1115 0.39 0%
a Standardized mean differences as calculated by Gøtzsche and Johansen [37] with a fixed-effect model.
Table 6. Risk ratios for the number of patients improved related to environmental strategy in the meta-analysis by Gøtzsche 
and Johansen [37]
Strategy RR 95% CI Patients (n) P-value I2
Sojourn high altitude NA NA NA NA NA
Total avoidance NA NA NA NA NA
Exposure-based NA NA NA NA NA
Concurrent bedroom 1.06 0.75 to 1.50 282 0.82 0%
   1 barrier 1.07 0.75 to 1.53 233 0.77 0%
   2-3 barriers 0.85 0.19 to 3.79 49 0.87 0%
Air purification 0.67 0.24 to 1.87 56 0.61 0%
Mixed strategies 1.01 0.73 to 1.40 338 0.96 0%
Gøtzsche & Johansen a 1.01 0.80 to 1.27 338 0.94 0%
a Risk ratios as calculated by Gøtzsche and Johansen [37] with a fixed-effect model.
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The opposite of this non-significant increase in the magnitude of the effect size was a 
decrease in the number of patients, which was low in the subgroup with two barriers (n 
= 246) and very low in the subgroup with air purification (n = 70). A similar and smaller 
tendency was observed in the outcome of medication usage. The subgroup with one 
barrier showed zero effect, compared to a small effect in the subgroup with air purification. 
However, the number of patients decreased from 1043 in the subgroup with one barrier 
to 72 in the subgroup with air purification. The absence of significance in air purification 
may be explained by the small number of patients studied. However, we cannot exclude 
the possibility that the variation in outcomes played a role. These results suggest that the 
reintroduction of strategies has the potential to alter the debate on effectiveness. As our 
analysis was post hoc, it indicates a need to include the strategy of mite allergen control 
as a factor when defining meta-analysis protocols [83].
G E N E R A L DI S C U S SION
A reintroduction of strategies
This review reintroduces previously defined strategies for mite allergen control. Both the 
concurrent bedroom interventions strategy and the exposure-based strategy were 
introduced in the early 1990s. These strategies did not attract much attention by 
researchers, possibly because these strategies were not published in peer-reviewed 
journals. Both textile-based strategies built on the first-line reduction or prevention of 
allergen emissions from textiles are of primary importance in patient practice. Other 
defined strategies include air purification and a sojourn to an (alpine) mite-free 
environment. The latter two strategies are sparsely studied and not commonly advised 
in patient practice, possibly due to their costs. Only the strategy of removing patients 
from an environment with high mite allergen exposure is clearly accepted as effective 
[14,24]. Most of the recent meta-analyses of textile-based mite allergen control for the 
treatment of asthma do not relate their findings to a strategy [37,39,40,42,44].
On textile-based strategies
A post hoc reanalysis of the dominant meta-analysis by Gøtzsche and Johansen [37] 
suggests that a majority of the trials examined had reported on the use of concurrent 
bedroom interventions executed in a minimal manner. The exposure-based strategy was 
not tested in the included trials. This result suggests that it is unknown whether the 
conclusion by Gøtzsche and Johansen [37] is valid for the exposure-based strategy. In 
our opinion, the choice of the strategy of concurrent bedroom interventions reflects the 
principals of traditional clinical trial design [84]. In a clinical experiment, the aim is to 
test for a possible difference between treatment and no treatment. A secondary aim in a 
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clinical experiment is to minimize the variance in outcomes to discriminate a treatment 
effect in as unbiased a manner as possible [85]. Among the many issues playing a role in 
minimizing variance in a trial, we consider the choice of a predefined simple and 
homogeneous treatment to be one, for instance, such as the choice of single bedding 
covers. However, the opposite of minimizing the variance is the considerable heterogeneity 
present in personal exposure. Studies on personal airborne exposure [86-88] show that 
relevant average exposure is not necessarily related to the sleeping site. Environmentally, 
emission sources, emission magnitudes, emission frequencies, and the presence of 
patients at emission sites may all vary. The considerable variance in exposure in patient 
practice calls for an exposure-based strategy. Nonetheless, we do not know of any study 
comparing the (clinical) effectiveness of the frequently tested strategy of concurrent 
bedroom interventions with the exposure-based strategy. This research question is 
relevant, as highly skilled health practitioners from France and The Netherlands advise 
their patients by use of the exposure-based strategy [89,90].
Recent studies
Additionally, recent studies have not related their findings to a specific strategy. Leas et 
al. [91] systematically reviewed the effectiveness of allergen control by subgrouping the 
control methods but not the strategies. In the review by Leas et al. [91], the assessment 
of the effect size remained unclear. Le Cann et al. [92] reviewed the effectiveness of home 
interventions for the treatment of allergy and respiratory diseases. They subgrouped 
interventions into three categories: education-based methods, physical methods, and a 
combination of both. Le Cann et al. [92] reported mixed results of these home 
interventions, urging further study of a multifaceted approach. Murray et al. [93] 
investigated the effect of mite-impermeable covers in a large randomized trial (n = 284) 
for the treatment of severe asthma exacerbations in children. In this trial, Murray et al. 
[93] reported a significant decrease in the primary outcome of hospitalization, which is 
sparsely studied in this field. We classified their intervention as the strategy of concurrent 
bedroom interventions using two barriers. From the observations by Murray et al., we 
assessed the SMD in asthma symptom score as -0.15 (95% CI: -0.41 to +0.12; P = 0.28), 
which fitted satisfyingly to our recalculation for the subgroup with two to three barriers.
Developing the debate?
What does our reintroduction of strategies add to the debate on allergen control? As 
stated above, the debate on the effectiveness of mite allergen control for asthma treatment 
has not been characterized by progress. Our reintroduction of environmental strategies 
of mite allergen control continues the call for re-thinking avoidance [17]. This call 
introduces the idea of improved measurement of personal exposure [88,94], reflecting 
the strategy of exposure-based control. Exposure-based control was not the subject of 
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study in any of the trials we analysed post hoc. The post hoc results of the subgroup of 
air purification are also of interest and have potential to influence the debate. For the 
concurrent bedroom interventions strategy, a question arises of the effectiveness of an 
intervention based on the full elaboration of this strategy, as this method has not yet been 
studied.
Other domains
Investigations on other allergic disorders caused by mites seem to show an identical 
tendency in strategies. Sheikh et al. [95] conducted a Cochrane review on the treatment 
of rhinitis and concluded that "extensive bedroom-based environmental control 
programmes may be of some benefit" and "evidence that isolated use of house dust mite 
impermeable bedding is unlikely to prove effective." Two trials stand out in this meta-
analysis. Terreehorst et al. [96] investigated the effectiveness of mite-impermeable covers, 
classified by us as the strategy of concurrent bedroom interventions using two barriers. 
This large trial (n = 279) did not show clinical benefits for the treatment of rhinitis. A 
small trial on comprehensive exposure-based control showed benefits in the treatment 
of rhinitis symptom scores and total IgE [97]. In the field of eczema, Kort et al. [98] 
showed identical benefits to those found by Kniest et al. in a case related to storage mites 
by use of the exposure-based strategy. These results underline the usefulness of 
introducing the strategy of mite allergen control in defining meta-analysis protocols.
C ONCLUSION
In summary, the clinical effectiveness of mite allergen control for the treatment of asthma 
is debatable [37]. It remains unclear whether the absence of evidence relates to a specific 
type of environmental strategy for mite allergen control, several of which were introduced 
in the early 1990s. A post hoc reanalysis suggests that the dominant conclusions by 
Gøtzsche and Johansen [37] relate to the strategy of concurrent bedroom interventions, 
which were mainly executed in a minimal manner. An evidence-based effectiveness 
assessment of the exposure-based control strategy, which is used in Western European 
patient practice, is still needed. Our post hoc findings indicate that future meta-analyses 
of mite allergen control should a priori define the environmental strategy under study. 
Future trials of mite allergen control are warranted to test the exposure-based strategy 
as well as the sparsely tested strategy of air purification.
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Effective control of house dust mite 
exposure from bedding materials
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A B ST R AC T
Background
Asthma is a heterogeneous disease. The subject of mite allergen control has evolved into 
a debate dominated by a Cochrane review by Gøtzsche and Johansen (Cochrane Database 
of Systematic Reviews, 2008, Art. No: CD001187). A not well-discussed aspect of that 
study is the selection by those authors of a univariate meta-analysis including various 
interventions. This study extends the meta-analysis by Gøtzsche and Johansen and aims 
to generate hypotheses on the effectiveness of various bedding interventions, including 
the coverage of all bedding elements.
Methods
Trials were selected based on environmental criteria. The interventions were classified 
according to the number of barriers used. Standardized mean differences yielded the 
mite load, three physiological outcomes and asthma symptom scores. The influence of 
covariates was examined with a mixed effect model using the metafor package for meta-
analysis in R. 
Results
Twelve trials included 1187 observations. The interventions included one barrier or 
product (6 trials), two barriers or partial control (4 trials) and three barriers or integral 
control (2 trials). The exposure data showed considerable heterogeneity (I2 = 93%). The 
risk of bias significantly (P = 0.04) influenced the final load, the square root of the 
interaction between the baseline load and the type of intervention as well (95% CI: -0.66 
to -0.07 μg/g; P = 0.02). Changes in load showed similar tendencies. Health outcomes 
showed moderate to considerable heterogeneity (physiological outcomes I2 = 44 to 94%; 
symptom score I2 = 93%).
Conclusion
A meta-regression of bedding interventions indicates that integral control most 
significantly reduced mite load when the load was high at baseline. The number of trials 
was too small to allow an appropriate examination of health outcomes. Future studies 
are suggested to test the hypothesis that allergic patients benefit from integral control 
when the baseline mite load is high.
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Background
We updated the meta-analysis published by McDonald et al. (Chest 2002;122;1535–1542) 
by reviewing the effectiveness of air purification for the treatment of home-related allergic 
asthma (dust mite, dog, cat, and cockroach).
Methods
We analysed the trials included by McDonald et al. as well as studies published since 
2000. Data on asthma symptoms scores (ASS), medication use, forced expiratory volume 
in 1 s as a percentage of the predicted value (FEV1 %pred), histamine provocative 
concentration causing a 20% reduction in FEV1 (PC20), Asthma Quality of Life 
Questionnaire (AQLQ) scores, and fractional exhaled nitric oxide (FeNO) levels were 
extracted. The effectiveness was examined using metafor (registered in Prospero 
CRD42019127227).
Results
Ten trials including a total of 482 patients (baseline characteristics: mean FEV1 %pred 
83.2%, I2 = 96.7%; mean PC20 4.93 mg/mL, I
2 = 44.0%; mean AQLQ 4.67 [max. 7], I2 = 
93.7%; mean FeNO 36.5 ppb, I2 = 0%) were included. We assessed the mean differences 
in the AQLQ scores as +0.36 (95% CI: 0.10 to 0.62, P = 0.01, n = 302, I2 = 0%) and the 
FeNO levels as –6.67 ppb (95% CI: –10.56 to –2.77, P = 0.0008, n = 304, I2 = 0%). The 
standardised mean differences in all other health outcomes were not significant (ASS 
–0.68, P = 0.20; medication use: –0.01, P = 0.94; FEV1 %pred –0.11, P = 0.34; PC20 +0.24, 
P = 0.53).
Conclusion
We found statistically significant mean differences in the AQLQ scores and FeNO levels 
in patients with predominantly mild to moderate asthma at baseline. A large trial reported 
great improvement in the subgroup of patients receiving Global Initiative for Asthma 
step 4 therapy. We recommend that future studies on air purification focus on patients 
with severe and poorly controlled allergic asthma.
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INTRODUCTION
Respiratory allergy is a public health problem that affects approximately 400 million people 
[1]. The most common home-related respiratory allergies result from house dust mite, 
dog, cat, and cockroach allergen (Global Initiative for Asthma, GINA, 2018). Therapies 
such as pharmacological treatment, immunotherapy, and avoidance of indoor allergen 
exposure have been developed for the treatment of allergic asthma [2]. Evidence of clinical 
benefits of textile-based avoidance strategies has not been demonstrated in rigorous 
systematic reviews [3–5]. In a scoping review, Boven et al. [6] observed potential success 
with the strategy of air purification for the treatment of house dust mite allergy-related 
asthma. Previously, McDonald et al. [7] reported improvements in asthma symptom scores 
(ASS) associated with air purification in a small patient subgroup (n = 88).
Whether the purification of indoor air is of clinical importance in patients with asthma 
remains an unanswered question. An allergic reaction is provoked in the upper airways 
after the deposition of aerosol particles in the epithelium. The faecal pellets of house dust 
mites are very small in size, at 10–40 μm (mean 22 μm), and decrease when they are 
partially degraded over time (diameter >0.5 μm) [8, 9]. A large proportion of cat and dog 
allergens are smaller than 2 μm in diameter and coagulate in the air to other aerosol dust 
[10]. The particle size of cockroach allergens is mainly >10 μm [11]. Industrial branches 
have developed specific filters (high-efficiency particulate air, HEPA, filters) that capture 
very small airborne particles with high efficiency (at least 85–99.999995% of particles 
with a diameter of 0.3 μm) [12]. These HEPA filters are applied in residential products 
such as housing ventilation units, mobile air cleaners, nocturnal temperature-regulated 
laminar airflow units, and vacuum cleaners. The strategy of air purification has a potential 
advantage over a textile-based control strategy because the former strategy traps airborne 
allergens emitted from clothes as well as emissions from indoor textiles. This advantage 
may explain the clinical potential of the air purification strategy. As the current evidence 
on the clinical effectiveness of the air purification strategy is based on small sample sizes 
and was obtained many years ago, there is a need to update the evidence base, as new 
devices for purifying the nocturnal breathing zone have been introduced [13, 14].
This study updates the existing systematic review by McDonald et al. [7] entitled 
“Effect of Air Filtration Systems on Asthma” by reviewing the clinical effectiveness of 
the air purification strategy for the treatment of home-related allergic asthma (house 
dust mite allergy, dog allergy, cat allergy, and cockroach allergy).
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METHODS
Reference search
The starting point of this study was the systematic review by McDonald et al. [7]. This 
meta-analysis included ten trials. An updated search of the literature published since 
January 2000 was performed in EMBASE, MEDLINE, and the Cochrane Central Register 
of Controlled Trials (CENTRAL). The trials were limited to peer-reviewed publications 
in the English language, and (Congress) abstracts were excluded from the analysis. The 
titles and/or abstracts of the studies retrieved during the search were screened (with 
Endnote) by the first author (F.E.v.B.) to identify randomised trials that met the inclusion 
criteria outlined below. The full texts of the potentially included trials were retrieved and 
assessed for inclusion by the first (F.E.v.B.) and second (N.W.d.J.) authors. Any ambiguities 
in the selections were resolved by discussion. The inclusion criteria were as follows:
• Type of study: randomised controlled trials with blinding.
• Intervention: housing or mobile ventilation systems, including HEPA filters but not 
vacuum cleaners.
• Participants: participants with physician-diagnosed bronchial allergic asthma. These 
participants had their sensitisation assessed by either skin testing or serum assays for 
specific IgE antibodies (house dust mite allergy, dog allergy, cat allergy, and cockroach 
allergy). The asthma assessment included a history of asthma symptoms and a 
pulmonary function test.
• Controls: participants who received a placebo or no treatment.
Data extractions and outcomes
The data were extracted by the first author (F.E.v.B.). The trials included in McDonald 
et al. [7] were re-extracted, as this review presented only the results but not the extracted 
data. The data extractions yielded the following: characteristics of the study population 
including the baseline data; type of intervention and the control; study methodology, 
and outcomes. Missing data were requested from the study authors. A second author 
(N.W.d.J.) verified the selections and the data extraction conducted by the first author. 
Any ambiguities in the selection and the extraction were resolved by discussion.
The main outcome(s) were: the asthma symptom score; the number of patients with 
improved outcomes; medication use; forced expiratory volume in 1 s as a percentage of 
the predicted value (FEV1 %pred); provocative concentration that causes a 20% reduction 
in FEV1 (PC20); Asthma Quality of Life Questionnaire (AQLQ) score, and the fractional 
exhaled nitric oxide (FeNO) level. Additional outcomes included: the mite allergen load 
from the mattress (μg/g dust); type of patient (child or adult), and the presence of primary 
and cosensitisation. These additional outcomes were all tested as possible explanatory 
variables in the presence of at least ten trials.
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For the ASS, the PC20, and the AQLQ scores, the final values were extracted (following 
Egbewale et al. [15]). The change scores were extracted for FEV1, medication use, and 
FeNO level. We defined the direction of changes as positive for an increasing FEV1 and 
negative for a decreasing FeNO level and medication use.
Risk of bias (quality) assessment
The risk of bias was assessed for the following domains: sequence generation, allocation 
concealment, blinding, incomplete outcome data, and selective outcome reporting. The 
assessment was performed by the first author (F.E.v.B.) with the Review Manager 
(RevMan) computer program version 5.3 (the Cochrane Collaboration, 2014; Nordic 
Cochrane Centre, Copenhagen, Denmark). A second author (N.W.d.J.) verified the 
assessments of the first author by considering a sample. Any ambiguities in the 
assessments were resolved by discussion.
Strategy for data synthesis
The effect size was set to the standardised mean difference, excluding the number of 
patients showing improvement (risk ratio). We chose the mean difference as the effect 
size in cases in which the outcomes were all measured in the same manner (AQLQ and 
FeNO). First, the overall effect of the health outcomes was estimated by a random-effects 
meta-analysis. Additionally, the I2 was calculated for examining heterogeneity in the 
outcomes. In the absence of heterogeneity (I2 = 0), a fixed-effects model was used. The 
explanatory variables of interest included the primary sensitisation (house dust mite 
allergy, dog allergy, cat allergy, or cockroach allergy), the mite allergen load from the 
mattress at baseline, possible confounding by the type of patient (child/adult), and the 
presence of cosensitisation. These outcomes were analysed for a preferred minimum of 
ten trials per variable [16]. All the calculations were performed with the metafor package 
in R [17, 18]. The level of significance was set to α = 0.05.
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RESULT S
Selection of the references
We selected and included studies in two groups of publications. First, we screened the 
ten trials included in the meta-analysis by McDonald et al. [7]. Three trials were excluded 
for a lack of or only partial reporting on the treatment of asthma [19, 20] or reporting 
incomplete data [21]. The remaining seven trials were included in the analysis [22–28].
The second group consisted of studies identified in our updated search (Figure 1) [29]. 
We identified a total of 1,000 titles and abstracts. A total of 971 titles were excluded for 
lacking randomisation and/or blinding regarding the effectiveness of air purification. 
 
 
 
 
Records identified through 
database searching 
(n =  1000 ) 
Additional records identified 
through other sources 
(n =  0 ) 
Records after duplicates removed 
(n =  1000 ) 
Records screened 
(n =  1000 ) 
Records excluded 
(n =  971 ) 
Full-text articles assessed 
for eligibility 
(n = 29  ) 
Full-text articles excluded, 
with reasons: 
- Not investigating a 
HEPA filter (n = 3) 
- Not treating asthma (n 
= 1) 
- Only abstract (n =  9) 
- Not a RCT (n = 13) 
 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 3  ) 
Figure 1. Flow chart of the reference search.
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Twenty-nine potentially relevant titles were selected for inclusion. We excluded twenty-
six full-text articles for not meeting our inclusion criteria (Appendix 2). Three full-text 
articles were included in the analysis [13, 30, 31]. In total, ten full-text articles were 
included in the meta-analysis.
Description of the trials and the baseline characteristics
Ten trials published between 1973 and 2012 reported the treatment of asthma by air 
purification (Table 1). In four trials, the primary sensitisation was a pet allergy [13, 27, 
28, 30]; five trials reported patients with house dust mite allergy [22–26], and one trial 
reported a mix of primary antigens [31]. None of the trials reported monosensitisation 
in the included patients. One trial [31] presented data on the specific IgE during the trial. 
Three trials reported the treatment of children with allergic asthma; the others reported 
the treatment of adults or both children and adults. Four trials studied nocturnal laminar 
airflow in the breathing zone; the other six trials studied the use of a home ventilation 
or mobile device with a HEPA filter. Only one trial reported on the airborne allergen 
exposure [28], five other trials reported on dust exposure or allergen load at baseline 
[24–27, 30]. In the trial by Warburton et al. [25] only the data on FEV1 %pred at baseline 
were available for analysis. In five trials, the mean FEV1 %pred was 83.2% (I
2 = 96.7%, n 
= 346). The mean PC20 was 4.93 mg/mL (I
2 = 44.0%, 2 trials, n = 29), the mean AQLQ 
score was 4.67 (max. 7; I2 = 93.7%, 2 trials, n = 304), and the mean FeNO level was 36.5 
ppb (I2 = 0%, 2 trials, n = 304). For the ASS and medication use, we had no (quantitative) 
data available at baseline. Ten trials reported on the use of medication at baseline. In four 
trials, the change in the use of medication was a primary outcome for measuring 
effectiveness [22, 25, 26, 28]. Two investigations instructed their patients not to change 
their medication [23, 27]. In two trials [13, 31], patients were allowed to use more 
medication. The risk of bias was judged as predominantly unclear with a low risk of bias 
in blinding (Figure 2).
Synthesis of the efficacy results
Four trials reported ASS as outcomes. We assessed the standardised mean difference in 
the ASS as –0.68 (95% CI: –2.21 to 0.85; P = 0.20; n = 77; I2 = 51.0%; Figure 3). The 
standardised mean difference in medication use was –0.01 (95% CI: –0.22 to 0.21; P = 
0.94; n = 401; I2 = 0%, 4 trials; Figure 4). In three trials, the standardised mean difference 
in FEV1 %pred was –0.11 (95% CI: –0.34 to 0.12; P = 0.34; n = 324; I
2 = 0%; Figure 5). 
Four trials reported on the PC20, with a standardised mean difference of +0.24 (95% CI: 
–0.85 to 1.33; P = 0.53; n = 98; I2 = 60.0%; Figure 6). The AQLQ scores were reported in 
two trials. We assessed the mean difference in the AQLQ scores as +0.36 (95% CI: 0.10 
to 0.62, P = 0.01, n = 302, I2 = 0%; Figure 7). This positive increase was strongly influenced 
by the large trial by Boyle et al. [31] (weight 77%). The mean difference in the FeNO level 
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was –6.67 ppb (95% CI: –10.56 to –2.77, P = 0.008, n = 304, I2 = 0%; Figure 8). None of 
the included trials reported on whether the physician-diagnosed numbers improved. 
Overall, the number of trials available was too small to allow any subgroup analysis.
Figure 2. Summary of the judgements on the risk of bias in the trials.
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Table 1. Characteristics of the included studies
Trial Use of a HEPA filter Subjects Primary allergy Health outcomes extracted
Zwemer [22], 1973 Nocturnal laminar airflow Child House dust mite ASS
Verrall [23], 1988 Nocturnal laminar airflow Adult House dust mite Medication use
Antonicelli [24], 1991 Mobile device Adult House dust mite ASS, medication use, FEV1 
%pred., PC20
Warburton [25], 1994 Mobile device Adult House dust mite FEV1 %pred.
Van der Heide [26], 1997 Mobile device Adult House dust mite PC20
Wood [27], 1998 Mobile device Adult Cat ASS, medication use
Van der Heide [28], 1999 Mobile device Child Cat or dog Medication use, PC20
Pedroletti [13], 2009 Nocturnal laminar airflow Adult Cat or dog AQLQ score, FeNO level
Sulser [30], 2009 Mobile device Adult Cat or dog PC20
Boyle [31], 2012 Nocturnal laminar airflow Adult House dust mite or cat Medication use, FEV1 
%pred., AQLQ score, FeNO 
level
-2.5 -1 0 1
Standardized Mean Difference
Wood, 1998
Antonicelli, 1991
Zwemer, 1973
18
9
12
17
9
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-0.39 [-1.06,  0.28]
-0.29 [-1.22,  0.64]
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-0.68 [-2.21,  0.85]RE Model for All Studies (I^2 = 51.0%)
Author(s); Year Sample sizes
n1 n2
Mean Std. diff. ASSs [95% CI]
Figure 3. Forest plot of the standardised mean differences in the ASS.
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Figure 4. Forest plot of the standardised mean differences in medication use.
Figure 5. Forest plot of the standardised mean differences in the FEV1 %pred.
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Figure 6. Forest plot of the standardised mean differences in the PC20.
Figure 7. Forest plot of the mean differences in the AQLQ scores.
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DISCUSSION
We reviewed the clinical effectiveness of the air purification strategy for the treatment 
of home-related allergic asthma in ten trials. The mean differences in the AQLQ score 
(MD = +0.36; P = 0.01) and the FeNO level (MD = –6.67; P = 0.008) were statistically 
significant, suggesting that asthma patients may benefit from air purification. These 
results were obtained in patients with predominantly mild to moderate asthma outcomes 
at baseline (the FEV1 %pred, the AQLQ score, and the FeNO level). The overall airway 
hyperresponsiveness was mild at baseline, according to the classification by Cockcroft 
et al. [32]. The risk of bias in the trials was predominantly judged unclear; however, 
blinding has a low risk of bias.
The strength of this meta-analysis was the rigorous selection of trials and extraction 
of data. We decided a priori whether to extract change or final values considering the 
statistical notes by Egbewale et al.[15]. In our study, we excluded some trials that were 
included by McDonald et al. [7] due to a critical process in extracting the data. For 
instance, they included the ASS by Reisman et al. [20]. After a critical review of this paper, 
we decided not to extract these data as only 11 of 32 patients were diagnosed with asthma; 
thus, we excluded this trial from the analysis. We noticed that this trial was also excluded 
for the same reason in the meta-analysis by Gøtzsche and Johansen [3]. While the 
previously analysed trials were quite old, the recent trials included the use of validated 
-20 0 10
Mean Difference
Boyle, 2012
Pedroletti, 2009
189
11
93
11
-7.13 [-13.55, -0.71]
-6.40 [-11.30, -1.50]
-6.67 [-10.56, -2.77]FE Model for All Studies (I^2 = 0.0%)
Author(s); Year Sample sizes
n1 n2
Mean diff. FeNO [95% CI]
Figure 8. Forest plot of the mean differences in the FeNO levels.
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outcomes such as the AQLQ score [33]. In patients with mild to moderate disease, we 
observed small (not reaching the minimum clinically important difference) but significant 
improvements in the AQLQ scores and FeNO levels. This effect could possibly be stronger 
in patients with severe asthma than in those with mild to moderate asthma. This possible 
tendency is well presented in the large trial by Boyle et al. [31]. They studied the 
effectiveness of the Protexo system (a nocturnal temperature-controlled laminar airflow) 
and reported the outcomes of the use of medication, FEV1 %pred, AQLQ scores, and 
FeNO levels. They differentiated the AQLQ score, their primary outcome, and the asthma 
status defined by the treatment intensity of GINA and the asthma control test (ACT). 
After a 1-year treatment period, Boyle et al. [31] reported an AQLQ score difference of 
+0.31 (P = 0.04) in all the studied patients (n = 282). When limited to the patients 
classified as requiring GINA step 4 therapy (GINA 4) at baseline, the difference became 
+0.47 (P = 0.04, n = 129). In the patients receiving GINA 4 with poor control (ACT <18), 
the difference in the AQLQ score was +0.70 (P = 0.02, n = 87). Additionally, in the 
patients with a high FeNO level at baseline, the same tendency was reported by Boyle et 
al. [31] (mean difference in FeNO –29.7 ppb, P = 0.001). 
The limitation of this meta-analysis was the relatively small number of trials included 
in the analysis. Our update did not result in many new included trials. In total, we 
included the same number of trials (n = 10) as McDonald et al. [7] included in their 
earlier meta-analysis. We had to exclude three trials that were included by McDonald et 
al. [7] because of a lack of reporting on the treatment of asthma or incompleteness of the 
data. McDonald et al. [7] previously reported “a small but statistically significant 
difference in total symptoms associated with use of domestic air filters.” They did not 
find benefits associated with medication use or morning peak flow values. In our update, 
we did not find a significant difference for the ASS outcome. The significance reported 
by McDonald et al. [7] was based on an analysis by the fixed-effects model. As the ASS 
showed moderate heterogeneity (I2 = 51%), we introduced the random-effects model 
and the significance was lost. The use of domestic HEPA filters will also be of relevance 
in the treatment of non-allergic asthma, for instance by filtering indoor air pollution. As 
we included only trials on the treatment of allergic asthma, this possible issue did not 
bias our results. The description of the allergen exposure differed in the trials and was 
sometimes poorly presented. Therefore, we could not analyse the degree of the exposure, 
and also cannot exclude the possibility that a variation of allergens from other sources 
affected the results.
The significant differences we found were both a result of trials sponsored by Airsonett 
AB (Angelholm, Sweden). One of these trials [31] was predominantly responsible for the 
positive AQLQ score analysis and was judged as having a risk of bias in randomisation. 
Their treatment group was twice the size of the control group. In principle, this creates 
a risk of selection bias as recruiters could “guess with greater than a 50% probability what 
CHAPTER 5
102   
the next treatment allocation will be” [34]. In their report, we did not find indications 
for baseline imbalances biasing the estimates. Another issue of relevance in both trials 
on the Protexo system is the possibility of changes in medication use. Pedroletti et al. 
[13] reported that “inhaled, short-acting beta-2 agonists were allowed as rescue 
treatment.” Boyle et al. [31] instructed that the patients “asthma medication were kept 
unchanged for the first 3 months, and thereafter adjusted to optimise asthma control.” 
We cannot exclude the possibility that these instructions confounded the significant 
results we found. Overall, the results require independent repeating, with careful 
monitoring of allergen exposure.
Other studies on the Protexo system resulted in (some) clinical benefits. Schauer et 
al. [35] observed reduced asthma exacerbation and hospitalisations in an observational 
study in patients with predominantly difficult-to-control asthma. In a recent pilot study, 
Gore et al. [36] reported the potential for the use of the Protexo system as an add-on to 
standard pharmacological treatment in children with difficult-to-control atopic 
dermatitis. These results also reflect the need to study patients with severe and 
uncontrolled conditions.
In brief, we reviewed the clinical effectiveness of the air purification strategy for the 
treatment of home-related allergic asthma (house dust mite allergy, dog allergy, cat allergy, 
and cockroach allergy). We found statistically significant mean differences in the AQLQ 
scores and FeNO levels in patients with predominantly mild to moderate asthma at 
baseline. A large underlying trial [31] showed potentially great improvement in the AQLQ 
scores in the subgroup of patients receiving GINA 4 therapy with poor control. Future 
studies on air purification strategies with rigorous trial designs that focus on patients 
with severe and poorly controlled allergic asthma are warranted.
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Background
House dust mites in Europe are dramatically reduced at high altitude (> 1500 m) because 
the micro humidity is too low to support the survival of mite populations. At high altitude, 
barometric pressure, oxygen content, outdoor temperature, and absolute outdoor 
humidity decrease. From an environmental viewpoint, it is not well discussed which 
physical phenomenon causes the absence of mites at high altitudes in Europe. The aim 
of this study was to systematically review the relationship between mite allergen exposure 
in Europe and altitude-related characteristics using existing data subsets.
Methods
Data were collected on mite allergen exposure at different altitudes in Europe from three 
earlier studies. For all locations, the oxygen percentage, the mean outdoor temperature 
in January and the barometric pressure were estimated. The mean mite allergen exposure 
rate for mattresses was set to the allergen load in Der 1 from mattresses or the mean 
number of mites divided by 50 for mattresses and 5 for carpets. The standard deviation 
of the exposure rate was calculated by imputation. Collinearity between altitude 
characteristics was tested with the condition number test. The relationship between the 
exposure rate and altitudinal characteristics was examined with a mixed effects model 
with the package metafor in R (version 3.1.2).
Results
Data from 35 sampling localities covered 4017 observations on mite abundance 
throughout Europe. The exposure rate varied from 0.01 to 36 μg/g dust, with a median 
of 1.05 μg/g dust, and showed considerable heterogeneity (Q = 3080; P < 0.0001; d.f. = 
34). The condition number φ ranged from 1.5 (oxygen percentage versus outdoor 
temperature) to 54.5 (oxygen percentage versus barometric pressure), indicating 
collinearity between the latter two variables. With regards to the subset analysed, the 
mixed effect models significantly explained the exposure rate using multiple variables 
related to altitude.
Conclusion
The results of this observational meta-regression on house dust mite exposure in Europe 
support earlier findings on the limiting effect of dry climates. Additionally, house dust 
mite allergen exposure around the European Alps showed an association with thin air 
at elevated altitude. These findings suggest future studies to test the hypothesis that 
multiple altitudinal characteristics including thin air limit house dust mite exposure in 
European Alps and urge for an experimental validation on house dust mite physiology 
at high altitude.

van Boven FE, Jong NW de, Loomans MGLC, Braunstahl GJ, 
Gerth van Wijk R, Arends LR.
Describing indoor house dust mite aeroallergen exposure: Inclusion of peak 
concentrations. European Aerosol Conference - EAC 2020 (abstract accepted)
The description of house dust mite 
aeroallergen measurement results
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Background
Measuring house dust mite aeroallergen concentrations is essential in understanding 
mite allergen exposure. We studied the statistical ways of summarizing measurements 
of fluctuating mite aeroallergen exposure inside homes. 
Methods
To study emissions from beddings, we measured the time-related airborne dust 
concentration after shaking a duvet. Analysis was performed both by a method based on 
the estimated mean and by a non-linear model. 
Results
In a sample of twenty-eight studies, all of them reported a sum of concentrations; only 
one also reported the peak concentration. This peak concentration was four times higher 
than the mean. In our four experiments on shaking a duvet (245 to 275 measurements 
each), the peak value was two to four times higher than the mean. The mean-based and 
non-linear models both predicted the sum of concentrations exactly. A 1% upper 
prediction bound and the non-linear model predicted the peak emission rate moderately 
well (64 to 92%, and 63 to 93%, respectively). 
Conclusion
Mean levels of mite aeroallergen measurements differ substantially from peak 
concentrations. The use of the mean is only sufficient to predict the sum of concentrations. 
We suggest that, mite aeroallergen measurements should include information on the 
peak as well as the mean.
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I N T RODU C T ION
Measuring house dust mite aeroallergen concentrations is essential in understanding 
personal mite allergen exposure [1]. The species of the mites Dermatophagoides, 
pteronyssinus, Dermatophagoides farinae, Euroglyphus maynei, as well as the specie Blomia 
tropicalis, are important domestic sources of house dust mite allergens, which are found 
mainly in their faecal products [2,3]. The spherical faecal particles, with diameters of 
10–40 μm [4], partially degrade with time into smaller fragments of 1–10 μm [5], which 
easily become airborne. Most large airborne mite allergens settle rapidly in five to twenty 
minutes after emission [6]. Environmentally, indoor exposure is characterized by the 
peak concentration (the largest amount of mite aeroallergen that a person is exposed to 
at any one time) and the sum of concentrations (the total amount of mite aeroallergen 
that a person is exposed to during a specified time) [7,8]. In daily life, patients are exposed 
in their homes to repeated environmental allergen emissions, followed by decays [4]. In 
the field of aerobiology, such diurnal fluctuating exposure is modelled with a tailored 
model, such as a time series or periodic function [9]. 
Methods for the measurement of airborne house dust mite particles during specific 
portions of the day or night, e.g. during sleep, have also been proposed [10]. Historically, 
experiments on exposure to indoor mite aeroallergens expressed variation in terms of 
either the mean concentrations during disturbed conditions or the mean concentrations 
during undisturbed conditions [4,11,12]. Sampling periods started from 20 minutes 
duration. Decades later, modern techniques show that fluctuations in indoor particle 
exposure take seconds to a minute [13]. However, from a statistical point of view, a not 
well-discussed topic is whether the use of mean concentrations can be improved by 
presenting more information on the peaks. Allergen levels for all particle sizes are very 
well correlated (R2 ≥ 0.92) with aerosol dust exposure [14]. This creates the possibility 
for using real-time aerosol dust exposure measurements as a proxy for observing these 
fluctuations. 
The aim of this study is to examine how dust mite allergen exposure levels inside 
homes statistically have been reported in the past, and then, to enquire into whether the 
commonest methods of reportage are indeed the best. Accordingly, we first search and 
summarize the literature on statistics of indoor aeroallergens measurements inside homes, 
and then experimentally study emission from bedding, paying special attention to the 
mean concentration, peak concentration, and sum of concentrations and using the 
methods of applied statistics. 
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METHODS
Summary of literature
A sample from the literature on indoor measurement of airborne mite-allergen exposure 
was selected from Pubmed and Web of Science by use of the keyword search-strings 
‘airborne AND mite AND (allerg* OR antigen* OR exposure)’ and ‘aeroallergen AND 
mite AND sampl*’. We searched for all references up to August 9th, 2019. The results were 
limited to those articles referring to measurements of airborne mite-allergen concentration 
inside homes and written in the English language. References were selected on the basis 
of their abstracts. We also screened for descriptions of the measurements as well as details 
of the indoor environment. Data were extracted for the airborne concentrations, the 
measuring periods, and the particle size distribution. The procedure is illustrated in 
Figure 1 [15]. For this summary of statistics from the literature, we focussed on three 
characteristics of exposure: the mean concentration during undisturbed conditions, the 
mean concentration during disturbed conditions, and the peak concentration. The mean 
is defined as “the arithmetic average of the observations” [16]. Thus, the mean-value can 
differ depending on measuring during various types of human activity: for instance, 
when measuring both under disturbed and undisturbed conditions. Only articles were 
included reporting time-related statistics or statistics categorized to different indoor 
conditions.
Pilot study 
In order to study the emissions from a bedding site, we measured the airborne dust levels 
in a bedroom of each of two Dutch family homes after shaking a duvet vigorously once 
or twice. One duvet was 16 years old, the other 4 years old. Both bedrooms were unheated 
and unused, with all ventilation devices off and the windows closed. Every six seconds, 
counts of particles in the size-range 0.25 to 32 µm were collected by an aerosol 
spectrometer (Grimm 1.109). Extractions from the datasets were confined to the period 
of mechanical activation of the duvet. Only data from the coarse fractions (particle 
diameters >2 μm) were used. A recent study has shown that large particles (>6 μm) tend 
to be deposited mainly in the upper airway, whereas particles in the size range 2–6 μm 
are deposited in the central and small airways [17]. In another study, Brown et al. observed 
that effectively all particles ≤1 μm penetrate (or pass) the extra-thoracic region as well 
as the tracheobronchial region [18]. These results indicate that particle sizes ≤ 1 μm are 
not of relevance in allergic asthma.
Total mass concentrations were obtained from the particle counts (assuming the 
particles to be made of material with a density of 1 g/cm3). We assessed the peak 
concentration and the sum of concentrations using of two approaches. The first method 
yielded an estimated mean for predicting the sum of concentrations, from which we 
127
THE DESCRIPTION OF AEROALLERGEN MEASUREMENT RESULTS
derived a 1% upper prediction bound Y0.99 = Y + t0.01;n-1 * S * √ (1+1/n)  for predicting the 
peak concentration (Y0.99 is the 1% upper prediction bound; Y is the estimated mean; t 
is the t-value; S is the standard deviation; n is the sample size). The second method used 
a nonlinear model Yt = β0 + β1*exp (-β2 * t) [8], where t is the time in seconds; Yt is the 
concentration at time t; β0 is a parameter representing the background concentration; β1 
is a parameter representing the concentration at t = 0 s; and β2 is a parameter representing 
the decay or settling rate of the dust concentration. We assessed the quality of the fit by 
the coefficient of determination R2. A sensitivity-analysis yielded the fitting for the first 
ten minutes after activation of the duvet. All calculations were performed in R, version 
3.4.1 [19]. The package minpack.lm was used for estimating the nonlinear model.
RESULT S
Literature search
We found 610 references related to the measurement of airborne house dust mite allergen 
concentration, of which 81 appeared to be duplicated (Figure 1). Fifty-seven full articles 
were selected for screening descriptions of the measurements. Twenty-eight studies 
reported on measurements of airborne dust mite exposure in the home environment. 
All of these summarized the measurements by use of the mean. Ten of these studies 
presented time-related results on indoor exposure, for instance after changing the bedding 
(Table 1; Refs. 4,6,10,12,20-25). Five studies used a volumetric air sampler [4,6,10,12,23], 
and one used an ionic sampler [20]. The other four studies used an intranasal sampler 
[21,22] or a personal sampler [24,25]. The mean concentrations during undisturbed 
conditions ranged from 0 to 1.7 ng allergen/m3, and the mean concentration during 
disturbed conditions ranged from 0.3 to 190 ng allergen /m3. These measurements were 
presented in various units (Der p1, allergen, protein). 
Only one study [6] presented a peak concentration (736 ng house dust mite allergen 
/ m3 after 5 min) rather than a mean. This study is particularly interesting because their 
measurements began with the changing and vigorous shaking of the bedding while 
measuring, and ran for 24 h. Mite antigen concentration (protein) was measured in five 
different particle sizes (<0.8 μm; 0.8–1.4 μm; 1.4–2.3 μm; 2.3–4.1 μm; >4.1 μm) after 
sampling for 5 min, 20 min, and 24 h. The concentration measured was 100% at 5 min, 
34.1% after 20 min, and 0.2% after 24 h. Also, other studies showed large differences 
between disturbed and undisturbed conditions. For instance, De Blay et al. [12] reported 
a ratio > 200 between both conditions, indicating a rapid settling of particles.
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Pilot study 
The four experiments began with shaking a duvet one or two times. In each experiment, 
245 to 275 measurements were made. The sum of concentrations in the experiments was 
1337 to 7083 ng/dm3 dust, compared to an initial concentration of 19.5 to 54.0 ng/dm3. 
The older duvet (16 years) caused a higher initial exposure than the younger duvet (4 
years). We achieved a perfect prediction (100%) of the sum of concentrations by both 
the estimated-mean method and the non-linear model for all four experiments. The 
percentage predicted initial concentration ranged from 64 to 92% (1% of the upper 
prediction bound), and 63 to 93% (nonlinear model) (table 2). The coefficient of 
determination R2 for the four experiments was 0.09; 0.07; 0.05; 0.03 (use of the mean) 
and 0.85; 0.85; 0.86; 0.93 (nonlinear model). (Figure 2-5). 
In a sensitivity analysis, we limited the data to the first ten minutes after activation of 
the duvet and found that the percentage predicted initial concentration ranged from 79 
to 105% (1% of the upper prediction bound), and 88 to 106% (nonlinear model). 
 
 
 
 
Records identified through 
database searching 
(n =  610) 
Additional records identified 
through other sources 
(n =  0) 
Records after duplicates removed 
(n =  529) 
Records screened 
(n =  529) 
Records excluded 
(n =  472) 
Full-text articles assessed 
for eligibility 
(n = 57) 
Full-text articles excluded; 
- not in English (n = 4) 
- not measured in a 
house (n = 25) 
- no time-related 
measurements (n = 
18) Studies included in 
summarizing statistics 
(n =  10) 
Figure 1. PRISMA Flow chart of the literature search.
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Table 2. Predictions of the peak concentration measured from shaking a duvet (duration of measurement six seconds)
Experiment
*
Shaking of the duvet
(age of the duvet)
Initial or peak 
concentration  
(ng/dm3)
1% upper prediction 
bound
(ng/dm3)
Prediction by 
non-linear model
(ng/dm3)
1 One time (4 years) 19.5 12.6 12.3
2 Two times (4 years) 21.5 14.3 16.7
3 One time (16 years) 31.9 26.4 23.6
4 Two times (16 years) 54.0 49.6 50.3
* Experiment 1-4 shown in figure 2-5.
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Figure 2. Measured and predicted dust concentration in experiment 1 after shaking a four-year-old duvet one time.
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Figure 3. Measured and predicted dust concentration in experiment 2 after shaking a four- year-old duvet two times.
Figure 4. Measured and predicted dust concentration in experiment 3 after shaking a sixteen-year-old duvet one time.
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DI S C U S SION
Measurement of personal mite aeroallergen exposure is complex. Early studies showed 
that human activities increased the mean aeroallergen levels [4,11,12]. The last 
development is the use of a small sampler, worn on the human body [25]. We investigated 
the way of describing the measurement of fluctuating indoor mite aeroallergen 
concentrations from beddings. 
A sample of fifty-seven articles on indoor measurements of airborne mite allergen 
exposure was taken from the literature. Only measurements in houses were considered. 
All articles summarized their results by the use of the mean (the arithmetic average of 
the observations), which is also sufficient to describe the sum of concentrations. Ten 
studies reported time-related indoor measurements, all including a mean during 
disturbed conditions and a mean during undisturbed conditions. A recent study on 
indoor aerosol dust particles suggests to measure fluctuations occurring during the 
disturbed and undisturbed conditions [13]. This is supported by the experiment by 
Swanson et al. [6], who showed relative differences of a ratio of 110 between disturbed 
and undisturbed conditions.
The peak concentrations measured by Swanson et al. [6] was four times higher than 
the mean of 20 minutes measurement. These results should be interpreted with caution, 
as the assays used by Swanson et al. [6] might vary considerably. In our experiments also, 
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Figure 5. Measured and predicted dust concentration in experiment 4 after shaking a sixteen-year-old duvet two times.
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peak values differed substantially from mean levels. Considering the differences between 
the measured emissions in our four experiments, shaking a duvet once or twice is not an 
easily reproducible disturbance. Again, however, the relative change was of importance 
in this case. Generally, the nonlinear model and a 1% upper bound predicted the peak 
level best when the variation in background exposure was low. Our data showed large 
fluctuations in the background levels, dominating the predicted decay after an emission, 
and reducing the quality of fit, especially for the nonlinear model. These large fluctuations 
can perhaps be explained by a heterogeneous distribution of the particles in the indoor 
air after the moment of emission. In general, the non-linear model fitted the data best 
(R2 ≥ 0.85 for data with large fluctuations). This fit improves when limiting the data to 
the first 10 minutes of measurement. However, the aim of our study was not necessarily 
to find the best predictive model, but rather the best way of describing the variation in 
the mite aeroallergen exposure.
The strength of this study is that, to our knowledge, this is the first study of how 
statistical principles should be applied to presenting results on airborne mite-allergen 
concentrations in combined disturbed and undisturbed conditions. Our pilot study 
showed tendencies consistent with the relative amounts found in the early experiment 
by Swanson et al. [6], indicating that the use of the mean alone is not sufficient to describe 
the fluctuating mite aeroallergen concentration from bedding. Multiple statistical models 
are available, like time series, a periodic function and regression [8,9]. Nevertheless, the 
wide ranges in reported results suggest that much more study of personal exposure is 
needed.
A major limitation of this study relates to the clinical implication. Clinically, it is clear 
that the increased allergen concentrations play a role in asthma symptoms [26]. However, 
it has yet to be confirmed whether asthma outcomes correlate with peak concentrations 
of house dust mite allergens. Laboratory experiments that have been performed on the 
relation between asthma outcomes and mite aeroallergen doses were mostly based on a 
homogeneous mite airborne dose [27-29]. Field studies in humans relating personal 
airborne mite-allergen levels to clinical symptoms of asthma are sparse. In 1996, Custovic 
et al. [30] performed a study on the correlation between domestic mite allergen exposure 
and asthma severity in 53 patients during sleep. The overwhelming majority (94%) of 
mean airborne observations during the night were under the lower limit of detection for 
the allergen assay. Correlations were described between the allergen load and several 
asthma outcomes. While all the correlations were statistically significant, their magnitudes 
were all moderate (R2 = 0.38 to 0.49). These results show that more research is needed 
to understand the relationship between exposure and clinical outcomes. The use of 
tailored statistics combined with respiratory characteristics (e.g. FEV1/FVC), may allow 
the assessment of the actual aerosol exposure in the human airways, and provide evidence 
for the causal relation between house dust mite allergen exposure and allergic asthma in 
atopic patients.
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In conclusion, measurements of indoor mite aeroallergen concentrations are 
commonly summarized by the mean. A recent study favours the use of peak exposure 
during disturbed conditions [13], calling for the use of other statistics than only the mean. 
We suggest that future studies describing mite aeroallergen measurements include 
information on the peak concentration as well as the mean. The measurements should 
be conducted with state of the art assay technology and more sophisticated mathematical 
models, such as regression or a time series analysis, should be used in the analysis.
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INTRODUCTION
Indoor allergen-related asthma is a variable disease of the lower conducting airways, 
affecting several million people worldwide [1]. In general, the management of the allergic 
reaction involves the control of the exposure and/or the immunologic reaction [2]. The 
initial medical interventions accepted in the treatment of allergic asthma in the 
Netherlands involved exposure avoidance by removing patients to an apparently allergen-
proof chamber [3], or a compatible sojourn in a Swiss alpine house with a dust mite-free 
environment [4]. Modern trials tested the clinical benefits of avoidance in randomized 
blinded experiments, resulting in an absence of evidence [5]. The debate on environmental 
means reached an impasse [6]. Meanwhile, the method of measuring personal exposure 
was developed, which assessed the airborne allergen concentration a person is exposed 
to at any point [7]. This novel approach showed that the site of highest allergen exposure 
varies for patients [8]. Personalized exposure was denoted as a possible explanation for 
the impasse on effectiveness [9]. However, this did not alter the state of evidence [10]. A 
question yet unaddressed is whether exploring the variance in asthmatic patients, their 
homes, the types of interventions, and possible new strategies for control, could restart 
the debate.
In this thesis, we systematically reviewed whether patients with allergic asthma benefit 
from environmental means of avoidance, with regard to the type of patient and differences 
in exposure, the strategy of choice, and the types of interventions, with a focus on house 
dust mite allergy-related asthma. Specific topics allow the exploration of oxygen content 
as a factor limiting dust mite survival and the description of personalized allergen 
exposure.
FINDINGS
Baseline characteristics in trials
Our study commences by addressing the Cochrane review on house dust mite control 
by Gøtzsche and Johansen [10]. This meta-analysis currently summarizes the effectiveness 
of 55 trials on house dust mite control for the treatment of asthma. The baseline 
characteristics of the trials investigated by Gøtzsche and Johansen [10] varied. We 
observed a mean house dust mite allergen load of 9.86 μg/g from the mattress of (95% 
CI: 5.66 to 14.05 μg/g dust), a mean standardized asthma symptoms score (ASS) of 0.13 
(95% CI: 0.08 to 0.18), a mean forced expiratory volume in 1 s percentage of predicted 
(%) (FEV1 %pred.) of 85.3% (95% CI: 80.5 to 90.1%), and a mean histamine or 
methacholine concentration that causes a 20% reduction in the FEV1 (PC20) of 1.69 mg/
mL (95% CI: 0.86 to 2.52 mg/mL). These levels suggest that several clinical trials included 
patients with rather mild to moderate asthma who were exposed to varying and, at times, 
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negligible levels of house dust mite allergen load. The moderate asthma outcomes were 
most likely modified by the use of asthma medication, reducing the scope for improvement 
in the trials (chapter 2), owing to which, no or negligible improvements were anticipated. 
The baseline characteristics suggest to investigate patients with more severe and 
uncontrolled asthmatic conditions during their exposure to high levels of house dust 
mite allergen. In our data, we only observed one trial [11] that reported this combination 
of patients with a severe outcome (bronchial hyper-responsiveness PC20 < 1.0 mg/mL) 
during exposure to a high allergen load (mean 16.0 μg/g dust). Ehnert et al. [11] reported 
a standardized mean difference in PC20 of + 1.19 (95% CI: 0.12 to 2.25; P = 0.03; n = 16; 
figure 1) after 12 months by treating asthmatic children using concurrent bedroom 
interventions (use of two barriers).
Strategies of avoidance
A post hoc re-analysis (chapter 3) suggests that the conclusions by Gøtzsche and Johansen 
[10] are valid for the strategy of concurrent bedroom interventions (an approach using 
combined a priori defined barriers for the treatment of the bedroom) as defined by Colloff 
[12]. This strategy was primarily executed in a minimalistic manner. The rarely tested 
strategy of air purification [13] exhibited potential in terms of the effect size; a medium 
reduction in the standardized mean difference (SMD) of the outcomes of the asthma 
symptom score (SMD = -0.53; n = 70) and a marginal reduction in medication usage 
FE Model
-6 -2.5 1 4.5 8
Standardized Mean Difference
Ehnert, 1992 16 1.19 [0.12, 2.25]
1.19 [0.12, 2.25]
Author; Year Baselineload
[ug/g dust]
SMD in PC20
[95% CI]
Figure 1. Standardized mean difference in PC20 after 12 months in 16 children with a bronchial hyper-responsiveness of PC20 
< 1.0 mg/mL while exposed to a high allergen load at baseline (mean 16.0 μg/g dust)  as reported by Ehnert et al. [11] using 
concurrent bedroom interventions (use of two barriers)
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(SMD = -0.17; n = 72) were observed. Both reductions were not significant (respectively 
P = 0.19 and P = 0.46), which could also be explained by the limited sample sizes. This 
potential was extended by the significant results we observed in an updated meta-analysis 
on air purification for the treatment of domestic environment-related allergic asthma.
The strategy of concurrent bedroom interventions
The strategy of concurrent bedroom interventions comprises three primary bedroom 
barriers, including mite-impermeable covers (barrier 1), monthly hot laundering of the 
bedding (barrier 2), and removal of the bedroom carpet (barrier 3) [12]. A meta-
regression of the strategy of concurrent bedroom interventions shows that greater the 
number of barriers introduced, more significant is the reduction in dust mite load when 
the load was high at baseline (P = 0.02) (chapter 4). One of the recommendations from 
this field is to reduce at least 90% of the house dust mite load to achieve clinical 
effectiveness [12]. We observed that the house dust mite load from the mattress was 
reduced by approximately 90% on combining at least three barriers in the bedroom 
(figure 2). 
The strategy of air purification
To investigate the potential of the air purification strategy, we updated the meta-analysis 
by McDonald et al. [13] by reviewing the effectiveness of HEPA filters for the treatment 
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Figure 2. Scatterplot of percentage reduced mite allergen load from the mattress versus the number of barriers used in the 
strategy of concurrent bedroom interventions
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of home-related allergic asthma (dust mite, dog, cat, and cockroach allergens) (chapter 
5). Similar to the trend observed in the baseline characteristics, several trials on air 
purification for the treatment of home-related allergic asthma studied patients with 
predominantly mild to moderate asthma outcomes, resulting in marginal improvements, 
with varying significance. We observed statistically significant mean differences in the 
Asthma Quality of Life (AQLQ) scores (MD = +0.36; P = 0.01; n = 302) and the Fractional 
exhaled nitric oxide (FeNO) levels (MD = -6.67 ppb; P = 0.0008; n = 304). The SMDs in 
the asthma symptom scores reduced not significant (SMD = -0.68, P = 0.20), the 
medication usage (SMD = 0.01, P=0.94), the forced expiratory volume in 1 second (FEV1 
%pred.) (SMD = -0.11, P=0.34), and the PC20 (SMD = + 0.24, P = 0.53) were not 
significant. The two trials [14,15] responsible for the significant improvements were both 
sponsored by Airsonett AB, Angelholm, Sweden. For both trials, the possibility that the 
use of medication modified the results cannot be excluded, necessitating independent 
and more rigorous replication studies. A pertinent question is whether the effectiveness 
of intervention would become significant in patients with more severe and/or uncontrolled 
asthma. In the data on air purification, this issue is recognized in the outcomes of AQLQ 
and FeNO. In both outcomes we observed marginal yet statistically significant 
improvements (MD = +0.36 in AQLQ; MD = -6.67 ppb in FeNO). Notably, the trial by 
Boyle [15] on the use of a nocturnal laminar airflow reported that in the data limited to 
patients classified as requiring GINA step 4 therapies with poor control (ACT < 18), the 
mean difference in AQLQ (+0.70; P = 0.02; n = 87) and FeNO (-29.7 ppb; P = 0.001; n 
= 87) became clinically and statistically significant. Another pertinent question is whether 
combining the air purification strategy with a textile-based strategy would improve the 
clinical effectiveness, as results indicate that the use of high-efficiency particulate air 
(HEPA) filters does not eliminate allergen emissions [16].
House dust mites and altitude
The abundance of house dust mites varies in various regions of Europe [17]. Dry winter 
climates are known to limit house dust mite populations [18]. This is supported by the 
observations of house dust mite allergen exposure in the Scandinavian countries and the 
European Alps [19]. At a high altitude, other environmental factors, such as the 
barometric pressure and oxygen content, change as well [20]. In a hypotheses-generating 
meta-analysis, we studied whether altitudinal characteristics concurrently affect the 
survival of house dust mite populations (chapter 6). We observed several associations 
between house dust mite allergen exposure and multiple altitudinal characteristics, 
including the barometric pressure and oxygen content. When limiting the sampling 
locations to areas around the European Alps, the house dust mite allergen exposure was 
only associated with the oxygen content, while it did not correlate to the outdoor 
temperature in January as a substitute for the indoor humidity. The results necessitate 
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an experimental validation of house dust mite survival at a high altitude when exposed 
to optimal climatic conditions. If the development of house dust mites would (additionally) 
be associated with the oxygen content, this could create the possibility for a new 
environmental limiting strategy. In that case, it could be explored whether temporarily 
limiting the oxygen content in domestic textiles controls the survival of house dust mite 
populations. 
Describing fluctuating house dust mite aeroallergen measurements
The paradigm of house dust mite allergen exposure relates to the bedding site [2]. Two 
recent pilots on the measurement of house dust mite aeroallergen exposure revealed 
exposure patterns varying with time [8, 9]. These pilots suggested that beds are not always 
the primary sites of exposure. Measurement of personal aeroallergen exposure is a 
relatively new concept [7]. We observed that the measurements of house dust mite 
aeroallergen exposure are commonly summarized using the mean (chapter 7). 
Furthermore, in a pilot on dust emission from the bedding site, we observed that the 
peak values differed substantially from the mean values (2:4 ratio), necessitating the 
measurement of daily house dust mite aeroallergen exposure using methods such as time 
series analysis. It remains to be addressed whether the use of more sophisticated 
mathematical models would alter the recent conclusions by Tovey et al. [9]. The study 
describing house dust mite aeroallergen exposure is based on the hypothesis that peak 
values are of relevance in the management of allergic asthma. This hypothesis is yet to 
be evaluated. In our meta-analysis of the strategy of air purification, significant 
improvements in AQLQ and the FeNO were observed using the Protexo (Airsonett, 
Angelholm, Sweden), contrary to the ASS and FEV1 outcomes [15]. In another 
environmental study, Gore et al. [16] observed that the Protexo preliminarily reduced 
the decay and the background levels of aeroallergen exposure, and not their peak levels. 
This reflects the relevance of peak exposure in the direct immune reaction.
GENER AL C ONSIDER ATIONS
Restarting the debate?
As mentioned earlier (see page 16), the debate on house dust mite allergen avoidance 
reached an impasse since only comments were added to the meta-analysis by Gøtzsche 
and Johansen [10]. No new data backed by the same level of evidence have been added. 
Our meta-analyses are backed by the same level of evidence, highlighting the limitations 
in the study by Gøtzsche and Johansen [10] in particular. The potential for possible novel 
insights restarting the debate follows from the discrepancies in the study that were not 
addressed to date. Studying the patients with severe and uncontrolled asthma, indoor 
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environments with a high degree of allergen exposure, and the use of appropriate 
strategies of avoidance would help ascertain whether the existing information will be 
altered. These discrepancies should be studied in a concurrent manner. We were not able 
to test these hypotheses simultaneously due to the absence of clinical trials meeting the 
eligibility criteria of these end-points, particularly trials studying textile-based strategies. 
In fact, we urge the design of new clinical trials on the effectiveness of environmental 
control in allergic asthma treatment. The next sections discuss elements of the 
discrepancies we observed.
Studying the patients with severe asthma: the epidemiologic evidence
An aspect that is not discussed extensively is the threshold level of house dust mite 
allergen exposure for development of asthmatic symptoms in sensitised patients. Early 
epidemiological studies defined a threshold level of 10 μg mite allergen per gram of dust, 
above which asthmatic patients with house dust mite allergy would be in risk of an asthma 
exacerbation [2]. Studies linking the house dust mite allergen load to the severity of 
asthma outcomes are rare. In a study of 53 asthmatic adults, Custovic et al. [21] reported 
a moderate correlation (R2 = 0.35 to 0.49) between several allergic asthma outcomes 
(PC20, peakflow, and FEV1 %pred.) and the exposure levels. This indicates that the 
threshold for symptom development differs for each patient, and a higher exposure 
corresponds to a greater number of patients at risk of displaying symptoms. In the study 
by Custovic et al. [21], a very low FEV1 %pred. (<50%) was reported in a patient exposed 
to considerably low levels of allergens (>1 μg Der p2/g dust). Considering these factors 
concurrently, we surmise that questions pertaining to the threshold level require 
additional insights.
Investigating houses with a high degree of allergen exposure
A relevant issue for future studies is to identify indoor environments with a sufficient 
degree of allergen exposure. This question is related to the expected humidity of the 
niches where house dust mites are detected. House dust mites require a high relative 
humidity to survive [22]. A few technical aspects can be considered with respect to this 
issue. In the Netherlands, the current building regulation requires the development of 
well-insulated housing facilities [23]. The thermal insulation results in a lower relative 
humidity in carpets due to an increased temperature [24], imposing greater restrictions 
on house dust mite reproduction. This tendency is confirmed by findings on exposure 
in energy-efficient buildings in Lausanne [25]. Conversely, environmental research 
indicates that the microclimate in the bedding is also affected by the generation of heat 
and moisture from humans [26]. Apart from this, four human factors influence the 
microclimate in carpets and beddings [27]: the use of a heating system, the arrangement 
of furniture in houses; the human-mediated increase in humidity, and the use of a 
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building ventilation system. Therefore, the microclimate in the niche is determined by 
technical factors such as thermal insulation and presence of building ventilation, as well 
as by human factors [27]. Finally, the climatic change will create a more humid outdoor 
climate worldwide, improving the indoor climatic conditions for house dust mite survival 
[28]. Therefore, identifying indoor environments with a high degree of allergen exposure 
in the Netherlands would become easier. Nevertheless, in an older and extensive Dutch 
epidemiological study on the effectiveness of mite-impermeable covers for preventing 
mite allergy, the mean house dust mite allergen load from the mattress ranged from 0.6 
to 5.1 μg/g dust during a period of eleven years [29]. This study presents the challenge 
of investigating patients exposed to high concentrations (>10 μg/g dust; [2]) of house 
dust mite allergens in the Netherlands. In countries with a warm and humid outdoor 
climate, such as in southern Europe or in the tropics, one will often detect higher levels 
of exposure [17]. 
Revisiting the exposure-based strategy?
Our meta-analyses were limited to results from peer-reviewed randomized blinded trials. 
The Cochrane methods recommend considering the inclusion of unpublished studies in 
systematic reviews [30]. Including data from unpublished trials reduces the risk of 
reporting bias. The only randomized blinded trial known to us from non peer-reviewed 
sources was conducted by Van Lynden- van Nes [31]. This thesis described the treatment 
of asthmatic children using the exposure-based strategy. While Kniest et al. [32] and Kort 
et al. [33] observed benefits using the same approach for the treatment of rhinitis and 
eczema, Van Lynden- van Nes [31] did not observe benefits in asthma treatment. Notably, 
Van Lynden- van Nes [31] also observed that 80% of the treatment group did not complete 
the exposure-based avoidance process. The latter is possibly the most relevant observation 
from this trial. It indicates that the evaluation of the exposure-based control necessitates 
an adaptive experimental design [34].
Notes on the policy of avoidance
The policy of avoidance is another issue of interest. In the general introduction, we 
introduced the concept of environmental neutrality (see page 15). This policy aims to 
bring the current exposure to a complete standstill. To the best of our knowledge, the 
application of this policy is yet to be studied. In the absence of environmental control (as 
recommended by Gøtzsche and Johansen [10]) this policy could hypothetically be 
relevant to patients’ practice. Custovic et al. [21] showed that the severity and clinical 
activity of allergic asthma is positively related to house dust mite exposure. Van der Pol 
et al. [35] showed that in patients with house dust mite-induced allergic asthma who 
were already exposed in their personal environment, a bronchial allergen challenge with 
house dust mite allergen resulted in increased immune responses. In other words, the 
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allergen challenge investigated by Van der Pol et al. [35] should be considered to 
correspond to an increase in personal exposure, which subsequently resulted in an 
increase in immunologic parameters. Its implication on patient practice remains unclear. 
In absence of environmental control of the house dust mite allergens, the allergen 
exposure is still expected to undergo a yearly rise based on ecological principles [36]. 
House dust mite populations will increase until the mites reach an optimal density [36]. 
This process of population development can take several years. Concurrently, the faecal 
products of house dust mites remain allergenic for several years [37]. Taken together, the 
immune response and related symptoms can hypothetically still worsen in long-term 
when control of allergen exposure is not practiced. Application of this hypothesis can be 
considered in the guideline by the American Academy of Allergy, Asthma, and 
Immunology, recommending positive on measures for avoidance [38]. To the best of our 
knowledge, this hypothesis has not yet been studied in a controlled setting.
Other discrepancies possibly playing a role
Finally, our meta-analyses were based on randomized trials conducted from 1976 [39] 
to 2017 [40]. In several outcomes, we observed unknown variability between the studies. 
A priori defined covariates such as house dust mite allergen exposure, adult versus child 
and/or co-sensitization did not explain the variability in the subgroups that we were able 
to investigate. Other possible relevant covariates could be the several medical issues that 
changed during the last decades, which also relate to the changes in the effectiveness of 
house dust mite allergen avoidance for the treatment of asthma. For instance, the 
guidelines introduced new pharmacological strategies for asthma management, such as 
the recent recommendation by GINA for treating adult patients using a symptom-driven 
method [in mild asthma] or a daily corticosteroid-containing inhaler [41]. As a result, 
the medication use at baseline altered in the period we studied. Another issue is that 
standardized questionnaires were introduced for measuring asthma control as well as 
the quality of life [42, 43]. Possibly, the non-standardized questionnaires were responsible 
for introducing variance. Additionally, changes in the measurement of the allergen 
concentration could play a role [7]. To investigate these possible explanatory variables, 
the results should be sub-grouped based on a specific period.
C ONCLUSIONS AND REC OMMENDATIONS
The current evidence on the absence of benefits of treating house dust mite-induced 
allergic asthma using environmental means is characterised by limitations in patient 
selection, their indoor environment, and is valid for the strategy of concurrent bedroom 
interventions. The discrepancies in existing research can be addressed by investigating 
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patients with more severe and uncontrolled asthmatic conditions, and adopting 
comprehensive environmental strategies for treating patients exposed to high house dust 
mite levels at baseline. Framing relevant future research questions for such non-studied 
subgroups might help us reverse the impasse in this debate. Apparently, the description 
of exposure in trials can be improved by measuring the airborne concentration of house 
dust mite allergens, and describing the peak as well as the mean exposures. We observed 
the potential of the strategy wherein air purification improves the AQLQ scores and 
FeNO levels of patients with home-related allergic asthma with the use of a nocturnal 
laminar airflow. Possibly, other environmental factors, such as oxygen content, offer new 
avenues for exploring controlling strategies.
It has been recommended previously that randomized trials on house dust mite 
avoidance should be methodologically rigorous [10]. Several factors influence the 
exposure to house dust mite allergens. The control of all these factors in a trial is 
complicated. Therefore, the design of adaptive trials should be considered. In addition 
to the recommendations by Gøtzsche and Johansen [10], we recommend future 
randomized controlled trials on environmental means to investigate the discrepancies 
presented above. Strategies of house dust mite allergen avoidance, including exposure-
based control, should be tested; the strategy of concurrent bedroom interventions should 
be executed with at least four barriers, and a purified nocturnal laminar airflow combined 
with a textile-based approach should be employed. 
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SUMMARY
Asthma is a heterogeneous disorder of the conducting airways. One of the factors 
responsible for the onset of allergic asthma is exposure to indoor aeroallergens, 
particularly to the allergen from house dust mites. Allergic asthma can be treated using 
pharmacotherapy, immunotherapy, and by avoidance of allergen exposure. At the highest 
level of evidence, no clinical benefits of avoiding indoor aeroallergen exposure were 
observed. The debate on the effectiveness of environmental control for the treatment of 
house dust mite allergic asthma reached an impasse. 
In this thesis, we investigate several aspects of the predominant Cochrane review on 
house dust mite allergen avoidance that have not been studied yet (Cochrane Database
of Systematic Reviews, 2008, Art. No: CD001187). First, we describe a meta-analysis 
of the baseline characteristics in the trials evaluated by Gøtzsche and Johansen (chapter 
2). In 45 trials, we could denote the house dust mite allergen load from the mattress 
(mean 9.86 μg/g dust, 95% CI: 5.66 to 14.05 μg/g dust), the standardized asthma symptom 
scores (mean 0.13, 95% CI: 0.08 to 0.18), the forced expiratory volume in one second 
(FEV1) % predicted (mean 85.3%, 95% CI: 80.5 to 90.1%), and the histamine or 
methacholine concentration that causes a 20% reduction in the FEV1 at baseline (mean 
PC20 1.69 mg/mL, 95% CI: 0.86 to 2.52 mg/mL). The outcomes indicate that several 
clinical trials investigated patients with rather mild to moderate allergic asthma who 
were exposed to varying and sometimes negligible levels of allergen. In more than half 
of the included trials (56%), patients used inhaled corticosteroids, possibly explaining 
the predominantly moderate asthma status at baseline.
Strategies of house dust mite allergen control have been defined before (chapter 3). 
Total avoidance and a sojourn to a house dust mite-free environment were methods 
adopted initially. In the nineties, two textile-based approaches were introduced: the 
exposure-based strategy and the concurrent bedroom interventions. Other strategies 
include the breathing-related and combined strategies. We executed a post hoc 
subgrouping of the results into categories based on the environmental strategy used for 
house dust mite allergen control, revealing that the current evidence primarily relates to 
the strategy of concurrent bedroom interventions, executed in a minimalistic manner. 
The rarely investigated strategy of air purification exhibits potential based on a non-
significant improvement of the asthma symptom scores (SMD = -0.53) and medication 
usage (SMD = -0.17) in a small sample size.
Concurrent bedroom intervention is the strategy predominantly evaluated in clinical 
trials (chapter 4). This strategy comprises three primary bedroom barriers (interventions), 
including a mite-impermeable cover (barrier 1), monthly hot laundering (temperature≥60 
oC) of the bed sheets (barrier 2), and removal of the bedroom carpet and soft toys (barrier 
3). An investigation of this strategy revealed that a majority of the clinical trials studied 
the effectiveness of a minimalistic execution of concurrent bedroom interventions (one 
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or two barriers). Only two small trials introduced the three barrier concept. Our post 
hoc re-analysis suggests that a greater number of barriers corresponded to a more 
significant reduction in dust mite allergen load when the load was high at baseline (P = 
0.02). The number of trials were considerably limited to allow an appropriate examination 
of health outcomes related to the execution of the concurrent bedroom strategy.
A strategy with significant clinical potential is the purification of indoor air (chapter 
5). We updated the existing meta-analysis on the effectiveness of the air purification 
strategy for the treatment of home-related allergic asthma. In two trials, we observed 
marginal yet significant improvements in the outcomes of the Asthma Quality of Life 
Questionnaire (AQLQ) score (MD = +0.36) and the fractional exhaled nitric oxygen 
(FeNO) levels (MD = -6.67 ppb) with the use of a nocturnal laminar filtered airflow. No 
effectiveness was observed in the standardized mean differences in the asthma symptoms 
scores (SMD = -0.68), the use of medication (SMD = 0.01), the FEV1 % predicted (SMD 
= -0.11), and the bronchial hyperresponsiveness PC20 (SMD = + 0.24). 
The abundance of house dust mites in Europe is associated with the mean outdoor 
temperature in January (P = 0.0006), which is a substitute for the indoor humidity during 
the winter season (chapter 6). When sampling locations were limited to areas around 
the European Alps, house dust mite survival was only associated with the oxygen content 
(P = 0.02). This suggests the possibility that oxygen content is an environmental factor 
limiting house dust mite survival.
The last study dealt with the issue of describing airborne allergen exposure 
measurement (chapter 7). Reports on the measurement of house dust mite aeroallergens 
reveal that these measurements are commonly summarized using the mean value. From 
the results of a pilot on dust emissions after shaking a duvet, we observed that peak 
concentrations differed substantially from mean concentrations (2:4 ratio). The statistical 
description of house dust mite aeroallergen exposure released from bedding materials 
necessitate the use of sophisticated mathematical models, such as a time series analysis.
On the basis of our meta-analyses, we conclude that the current evidence on the 
absence of benefits of the treatment of house dust mite-induced allergic asthma using 
environmental means is characterised by limitations in the selection of the patients, their 
indoor environment, and the type of intervention evaluated. The discrepancies include 
the consideration of patients with more severe conditions who were also exposed to high 
allergen concentrations, and the testing of comprehensive control strategies. The fourth 
meta-analysis indicates the potential of the air purification strategy marked by the 
improvement of the AQLQ scores and the FeNO levels in patients with home-related 
allergic asthma. An observational meta-analysis on altitudinal characteristics suggests 
new opportunities for exploring oxygen content as a limiting factor for house dust mite 
survival. Based on the sixth study, we recommend that future studies should describe the 
house dust mite aeroallergen exposure using both peak and mean values.
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SAMENVAT TING
Astma is een ziekte van de onderste luchtwegen die veel variatie kan vertonen. 
Blootstelling aan binnenhuisallergenen, in het bijzonder die van de huisstofmijt, is een 
belangrijke oorzaak van de ontwikkeling van allergisch astma. Allergisch astma kan 
worden behandeld met medicatie, immunotherapie en het vermijden van blootstelling 
aan allergenen. Op het hoogste niveau van bewijs konden echter geen klinische 
verbeteringen worden aangetoond voor het vermijden van binnenhuisallergenen ter 
behandeling van astma. Het debat over de effectiviteit van vermijden van huisstofmijt 
allergenen voor de behandeling van allergisch astma kwam in een impasse terecht.
Dit proefschrift bestudeert meerdere nieuwe aspecten van de overheersende Cochrane 
review van Gøtzsche en Johansen naar het vermijden van huisstofmijt allergenen 
(Cochrane Database of Systematic Reviews, 2008, Art. No: CD001187). Eerst evalueren 
we de beginwaarden uit de trials die Gøtzsche en Johansen bestudeerden, door middel 
van een meta-analyse (hoofdstuk 2). In vijfenveertig trials vonden wij de allergeen 
expositie van de matras beschreven (gemiddeld 9.86 μg/g stof, 95% BI: 5.66 tot 14.05 
μg/g stof), een gestandaardiseerd astma symptoom score (gemiddeld 0.13, 95% BI: 0.08 
tot 0.18), een “forced expiratory volume in 1 second (FEV1)” (het uitgeblazen luchtvolume 
tijdens de eerste seconde van de test) in voorspeld percentage (gemiddeld 85.3%, 95% 
BI: 80.5 tot 90.1%), en de histamine- of metacholine concentratie waarbij het FEV1 20 
procent daalt (gemiddelde PC20 1.69 mg/mL, 95% BI: 0.86 tot 2.52 mg/ml). Deze 
uitkomsten suggereren dat in veel klinische trials patiënten met vrij mild tot matig astma 
zijn bestudeerd, die waren blootgesteld aan wisselende en soms verwaarloosbare niveaus 
van binnenhuis allergenen. De matige astma status bij aanvang van de studies wordt 
waarschijnlijk verklaard door het gebruik van corticosteroïden, wat in meer dan de helft 
van de studies (56%) speelde.
In de loop der jaren zijn diverse strategieën ter vermijding van huisstofmijt allergenen 
gedefinieerd (hoofdstuk 3). Totale vermijding en verblijf in een mijtvrije omgeving 
werden als eerste geïntroduceerd. In de negentiger jaren volgden twee textielgebaseerde 
aanpakken; de “expositie gebaseerde strategie” en de “samengestelde 
slaapkamermaatregelen”. Andere strategieën richten zich op de binnenlucht, als ook het 
mixen van strategieën. Een post hoc- categorisering van de resultaten van Gøtzsche en 
Johansen naar strategieën toont dat de samengestelde slaapkamerinterventies verreweg 
het meest zijn bestudeerd, daarbij vaak op een minimale wijze uitgevoerd. De schaars 
beproefde strategie van luchtzuivering toonde potentie via een niet-significante 
verbetering in het astma symptoom score (SMD = -0.53) en het gebruik van medicatie 
(SMD = -0.17) in een kleine steekproef.
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De klinische trials naar vermijding van blootstelling aan allergenen worden 
gedomineerd door het testen van de strategie van de samengestelde slaapkamer 
interventies (hoofdstuk 4). Deze strategie is opgebouwd uit drie primaire interventies 
in de slaapkamer, te weten het toepassen van allergeenvrije hoezen (barrière 1); het 
maandelijks heet wassen (temperatuur ≥ 60 oC) van alle lakens (barrière 2); en het 
verwijderen van overige textiel uit de slaapkamer (tapijt en knuffeldieren) (barrière 3). 
Uit een verkenning naar deze strategie blijkt dat de meeste trials een minimale uitvoering 
van de samengestelde slaapkamerinterventies hebben bestudeerd (één of twee barrières). 
Twee kleine trials bestudeerden een interventie bestaande uit drie barrières. Een post 
hoc heranalyse van de resultaten van Gøtzsche en Johansen geeft aan dat des te meer 
barrières worden geïntroduceerd, des te meer allergeen expositie wordt gereduceerd als 
deze bij aanvang van de studie hoog is (P = 0.02). Het aantal beschikbare trials was in 
deze heranalyse te klein om de klinische effectiviteit te kunnen beoordelen.
Een strategie die klinische potentie vertoond is luchtzuivering (hoofdstuk 5). Een 
oudere meta-analyse (2002) naar de effectiviteit van luchtzuivering binnenshuis ter 
behandeling van allergisch astma is bijgewerkt. In twee trials naar luchtzuivering direct 
boven het bed verbeterde de uitkomsten kwaliteit van leven bij astma (MD = +0.36) en 
de fractie uitgeademde stikstofoxide (MD = -6.67 ppb) beperkt doch significant. Geen 
significant verschil werd gevonden voor de gestandaardiseerde astma symptoom score 
(SMD = -0.68), het gebruik van medicatie (SMD = 0.01); het voorspelde percentage FEV1 
(SMD = -0.11); en de bronchiale hyperreactiviteit PC20 (SMD = +0.24).
De verdeling van huisstofmijten over Europa is gerelateerd aan de gemiddelde 
buitenluchttemperatuur in januari (P = 0.0006), als maat voor de binnenluchtvochtigheid 
in het winterseizoen (hoofdstuk 6). Als de data van huisstofmijtenexpositie over Europa 
worden beperkt tot een gebied direct rondom de Alpen, blijft alleen nog een associatie 
tussen de expositie en het zuurstofgehalte van de lucht over (P = 0.02). Dit suggereert 
dat het zuurstofgehalte van de lucht ook een beperkende factor zou kunnen zijn voor 
huisstofmijtpopulaties.
Het laatste hoofdstuk is gewijd aan het beschrijven van meetgegevens van aerosole 
allergeenexpositie (hoofdstuk 7). Publicaties over metingen naar aerosole huisstofmijt 
allergenen beschrijven deze in het algemeen met het gemiddelde. In een pilot naar stof 
emissie uit geschud beddengoed blijkt dat piekexposities veel verschillen van de 
gemiddelde blootstelling (verhouding 2 tot 4). Het beschrijven van aerosole huisstofmijt 
allergenen vraagt om het gebruik van maatwerk statistieken, zoals een tijdreeks analyse.
Op basis van onze meta-analyses concluderen wij dat het huidige gebrek aan bewijs voor 
klinische effectiviteit van vermijding aan blootstelling voor de behandeling van astma 
wordt gekenmerkt door beperkingen. Minder of niet bestudeerd zijn patiënten met 
ernstig en ongecontroleerde astma, blootgesteld aan een hoge allergeen expositie. Qua 
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strategie dienen uitgebreide interventies te worden getest. De vierde meta-analyse laat 
potentie zien voor de strategie van luchtzuivering middels verbeteringen in de kwaliteit 
van leven en de fractie uitgeademde stikstofoxide. Een meta-analyse naar hooggebergte 
karakteristieken en huisstofmijtenexpositie suggereert nieuwe kansen voor onderzoek 
naar het zuurstofgehalte als beperkende factor voor de huisstofmijt. Uit de laatste studie 
volgt het advies om in volgende studies de aerosole huisstofmijtallergenen zowel met 
piekwaarden als het gemiddelde te beschrijven.
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course on environmental noise control at the Hogeschool Amsterdam.
After graduating, Frank was employed for several years in the industry of building 
products in both building physic and consulting engineering. He worked as a policy 
maker for safety management for the city of Capelle aan den IJssel, as of December 1999. 
During the period 2000 through 2006, Frank taught Dutch respiratory care-nurses the 
basics of building physics for the Dutch Stichting Specifieke Scholing Verpleegkundigen 
(SSSV) in Bunnik.
The period at SSSV laid the foundation for the current research on house dust mite 
allergen avoidance. From 2007 to 2008 Frank was a visiting researcher at the chair of 
Public Health Engineering for Built Environments (PHEBE) of Eindhoven University of 
Technology. At PHEBE, he studied the relationship between dust mites and indoor 
environment, and guided students. A visit to the Congress of the European Academy of 
Allergy and Clinical Immunology of 2009, Warsaw, attracted his attention to the debate 
on the clinical effectiveness of house dust mite allergen avoidance. He now is a researcher 
at the Section of Allergology and Clinical Immunology, Department of Internal Medicine, 
Erasmus Medical Center Rotterdam. At the Section of Allergology and Clinical 
Immunology, he studies interdisciplinary issues in the debate on the clinical effectiveness 
of allergen avoidance. 
In 2004 he married Leilani Ruma and in 2006 their son Rodney was born.
CHAPTER 9
160   
PORTFOLIO
Publications
Peer-reviewed publications
- Boven van, F. E., De Jong, N.W., Braunstahl, G. J., Arends, L.R. & Gerth van Wijk, R., 
(2020), Effectiveness of the air purification strategy for the treatment of allergic 
asthma: a meta-analysis, International Archives of Allergy and Immunology 2020, 
DOI: 10.1159/000506284
- Boven van, F. E., De Jong, N.W., Braunstahl, G. J., Gerth van Wijk, R., & Arends, L. R. 
(2020), A meta-analysis of baseline characteristics in trials on mite allergen avoidance 
in asthmatics: room for improvement, Clinical and Translational Allergy, 10:2, 1-12
- Boven, F. E. van, Arends, L. R., Braunstahl, G. J., & R. Gerth van Wijk, (2019). A 
reintroduction of environmental mite allergen control strategies for asthma treatment 
and the debate on their effectiveness. Clinical & Experimental Allergy (49), 400–409
- Boven van, F.E. (2014), Effectiveness of mite-impermeable covers: a hypothesis 
generating meta-analysis, Clinical & Experimental Allergy (44), 1473-1483 
Book chapters
- Boven van, F.E. (2015), House dust mites and altitude, In: T. White (Ed.), Termites 
and Mites: Distribution Patterns, Biological Importance and Ecological Impacts (Nova 
Science Publishers)
Conference abstracts
- Boven van, F.E., De Jong N.W., Loomans M.G.L.C., Braunstahl G.J., Gerth van Wijk 
R., Arends L.R. (2020), Describing indoor house dust mite aeroallergen exposure: 
Inclusion of peak concentrations, European Aerosol Conference - EAC 2020 (abstract 
accepted)
- Boven van, F.E. (2013), Dose response for predicted FEV1: a preliminary meta-
analysis, European Congress of Epidemiology, Aarhus, Denmark (poster)
- Boven van, F.E. and R. Gerth van Wijk (2013), Asthma outcomes and mite allergen 
bedding control: a revisited meta-analysis, 2nd Sleep and Breathing Conference, Berlin, 
Germany (poster)
- Boven van, F.E., J.E.M.H. van Bronswijk and S. Kuhnt (2010), Combined 
environmental characteristics affecting mite-allergen load (Acari) in a small sample 
from Dutch mattresses, 29th Congress of the European Academy of Allergy and 
Clinical Immunology, London, United Kingdom (oral presentation)
- Boven van, F.E. and G. Schober (2010), Is mite allergen exposure at high altitudes 
affected by multiple environmental characteristics?, 29th Congress of the European 
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Academy of Allergy and Clinical Immunology, London, United Kingdom (oral 
presentation)
- Boven van, F.E. (2010), Concepts of applying impermeable covers for control of 
asthma: a preliminary review, 29th Congress of the European Academy of Allergy and 
Clinical Immunology, London, United Kingdom (poster)
- Boven van, F.E. (2009), Reproducibility of questions on environment characteristics 
related to mite allergen load independent from education on environment, 28th 
Congress of the European Academy of Allergy and Clinical Immunology, Warsaw, 
Poland (poster presentation)
- Boven van, F.E. (2009), Assessing airborne exposure from beddings by means of 
environmental engineering, 28th Congress of the European Academy of Allergy and 
Clinical Immunology, Warsaw, Poland (poster)
- Boven, F.E. van, S. Kuhnt and J.E.M.H. van Bronswijk (2008), Combined analysis of 
environmental characteristics affecting mite allergen load (Acari) in Dutch bedrooms, 
Indoor Air, Copenhagen, Denmark (oral presentation)
Invited lectures
- Boven van, F.E. (2011), Closed or open doors? Avoidance of indoor allergen and 
pollutant exposure, Rotterdam (pre-congress of International Society for Aerosols in 
Medicine)
Education, courses and workshops
- July 2019, Research integrity, Erasmus Medical Center, Rotterdam (1 day course)
- February 2015, Ontwikkelen van een Cochrane Review over interventies, Cochrane 
Netherlands (2 days workshop)
- July - October 2014, Understanding Research: An Overview for Health Professionals, 
University of California, San Fransisco (online course, Coursera)
- March - May 2014, Academic writing English, Leiden University (5 days course)
- June 2013, workshop “The New Statistics” by Geoff Cumming, Utrecht University (1 
day)
- January 2007 – November 2008, Publication class, Chair Public Health Engineering 
for Built Environments, Eindhoven University of Technology
- Sept. 1995 – Jun. 1996, Amsterdam University of Applied Sciences, Post-course 
environmental noise control
- Sept. 1991 - Aug. 1994, Eindhoven University of Technology; Faculty of Building and 
Architecture, building physics; Graduated in the field of biotic agents in the built 
environment (Elective lectures were attended in mathematical statistics)
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- Aug. 1987 – Jul. 1991, Utrecht University of Applied Sciences; Faculty of Building 
Technology (graduated with distinction)
Teaching
- 1999 – currently, instructing of Dutch respiratory nurses in technical diagnoses of 
the indoor environment, and methods of allergen avoidance
	 •	 	Stichting Specifieke Scholing Verpleegkundigen, Bunnik (Applicatiecursus Saneren, 
1999 to 2006)
	 •	V&VN Longverpleegkundigen, Utrecht (workshops 2011, 2013, 2014, 2016, 2019)
	 •	Antonius Academie, Utrecht (Course Asthma / COPD, as of 2017)
	 •	Davos Asthma on Top (2019)
- 2007 – 2008, Instruction of Bachelor and Master students, Chair of Public Health 
Engineering for Built Environments, Eindhoven University of Technology
	 •	2007: Health and Comfort seven students
	 •	2008: Robotics three students
	 •	2008: Health and Comfort six students
Miscellaneous
Bachelor-students
Supervising internalships at Municipal of Capelle aan den IJssel including writing of the 
Bachelor-thesis: six students (2012 – 2017).
Memberships
July 2006 – currently, Member of the Dutch commission on allergen avoidance, V&VN 
Lung Care nurses, Utrecht (Acting Chairman as of November 2012)
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Allergeenvermijding is een onderwerp dat mij al gedurende zeer lange tijd interesseert. 
Tijdens mijn studie Bouwfysica aan de Technische Universiteit Eindhoven van 1992 tot 
1994 kon ik via de leerstoel van prof dr. Annelies van Bronswijk al kennis maken met 
onderzoek naar de huisstofmijtenallergie. Rond de millennium-wisseling startte ik met 
lesgeven in toegepaste bouwfysica aan longverpleegkundigen (1999-2006) bij de Stichting 
Specifieke Scholing Verpleegkundigen. Centraal stond de vraag hoe een bouwkundige 
een woning analyseert. Ideeën ontstonden over een gestandaardiseerd bouwkundig 
meetinstrument voor de longverpleegkundige en ook het vraagstuk van allergeenarm 
wonen. Daarna keerde ik voor een korte periode terug naar prof.dr. Annelies van 
Bronswijk en volgde deelname aan haar publicatieklas. Hiermee kwam er meer structuur 
in mijn onderzoek en het beschrijven van de bevindingen. Waar ik mij eerst nog richtte 
op de allergeenarme woning, werd ik in 2009 door het bijwonen van een lezing van prof.
dr. Roy Gerth van Wijk over allergeenvermijding op het EAACI-congres met de neus op 
de feiten gedrukt. Er bleek geen evidence (meer) te zijn dat patiënten er baat bij hebben. 
Tijdens het lezen van het verantwoordelijke wetenschappelijke artikel van prof.dr. 
Gøtzsche en dr. Johansen (2008) viel ik al snel van de ene in de andere verbazing. Alle 
vormen van saneren werden ongeordend en in een eenvoudige analyse samengevoegd. 
Een nog belangrijker onderzoeksvraag openbaarde zich vervolgens dan het ontwerp van 
een allergeenarme woning, namelijk wat is het medische effect van saneren. Het belang 
van deze vraag werd bij iedere bijeenkomst van de werkgroep Saneren van de 
Verpleegkundigen & Verzorgenden Nederland onder leiding van Tiny Rooijendijk weer 
onderstreept en zorgde voor een belangrijke stimulans om door te blijven gaan. En nog 
steeds is het een belangrijk aandachtspunt in bijeenkomsten met de huidige leden Yvonne 
Verkooijen, Marieke Roest en Joke Hes. Dit alles leidde ertoe dat ik me ging verdiepen 
in het bewijs van effecten van allergeen vermijding op de klachten van de allergische 
patiënt. Met dank aan de nodige hulp van een groep mensen is het resultaat dit 
proefschrift.
Allereerst wil ik graag mijn promotor prof.dr. Roy Gerth van Wijk bedanken. Beste 
Roy, onze eerste ontmoeting dateert van rond 2009 toen wij het hadden over allergeenarm 
wonen. Nadat er een plan kwam voor het opnieuw bestuderen van de effectiviteit van 
allergeenvermijding, omarmde jij dit plan. Op natuurlijke wijze organiseerde jij een 
interdisciplinaire begeleiding, met ruimte voor iedere discipline voor zowel passende 
inbreng als samenwerking, waarvoor ik je graag wil bedanken. Ik wil je ook graag 
bedanken voor jouw strategische inbreng tijdens de onderzoeken, waardoor een artikel 
met een gewijzigde opzet kon worden gepubliceerd. Jouw begeleiding was altijd positief-
kritisch, constructief en op samenwerking gericht. Bedankt voor het in mij gestelde 
vertrouwen. 
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Prof.dr. Lidia Arends, promotor. Beste Lidia, naast wetenschapper ben je ook heel 
sociaal, en jouw samenwerking met prof.dr. Roy Gerth van Wijk verliep dan ook van het 
begin prettig. Op subtiele wijze heb jij veel invloed gehad op mijn proefschrift. Niet alleen 
door het zetten van de punten op de “i” in mijn analyses, maar ook jouw sturing om het 
wiskundig eenvoudig en tegelijkertijd wetenschappelijk te houden verdient een 
vermelding. Wiskunde ligt mij na aan het hart. Anderzijds is het ook belangrijk om het 
werk geaccepteerd te krijgen onder clinici. Ook jouw begeleiding was altijd constructief 
en op samenwerking gericht. Graag wil ik ook jou bedanken voor het in mij gestelde 
vertrouwen.
Dr. Nicolette de Jong, co-promotor. Beste Nicolette, jij werd in een wat later stadium 
betrokken in het onderzoeksproject. Jouw rol lag naast inhoudelijke inbreng ook in het 
schenken van aandacht aan de wetenschappelijke mores rondom het schrijven van 
artikelen, die mij minder bekend zijn. Door jouw inbreng was het ook mogelijk de latere 
meta-analyses met dubbele data-extracties uit te voeren. Dat heeft de wetenschappelijke 
waarde flink verhoogd, en bijgedragen aan de acceptatie van de artikelen. Gaandeweg 
bleek dat wij elkaar versterken in het onderzoek. Waar ik graag wat afstand neem om 
alles nog eens te overdenken, geef jij juist gas bij. Dat was op het einde ook wel eens nodig. 
Ik wil je graag bedanken voor onze samenwerking en de energie die jij op het juiste 
moment hebt ingebracht!
Dr. Gert-Jan Braunstahl, co-promotor. Beste Gert-Jan, jij reageerde altijd snel op mijn 
concept-teksten. Belangrijk waren jouw adviezen om (kleine) bevindingen meer te 
etaleren. Wetende dat juist in het longdomein de afwezigheid van het bewijs van 
allergeenvermijding als interventie domineert, was jouw steun als longarts heel belangrijk 
om toch door te blijven gaan. Ik wil je graag bedanken voor misschien wel het belangrijkste 
aspect in het schrijven van de artikelen, meedenken en het oog blijven houden voor de 
klinisch gerichte lezer bij mijn “wat” technische schrijfstijl.
Graag bedank ik de leden van de kleine commissie, prof.dr. Johan de Jongste, prof.dr. 
Helianthe Kort en prof.dr. Patrick Bindels voor het kritisch lezen en beoordelen van dit 
proefschrift, alsmede de adviezen voor de laatste verbeteringen. De overige leden van de 
commissie wil ik bedanken voor hun bereidheid zitting te nemen in de promotiecommissie.
Dr. Marcel Loomans, Technische Universiteit Eindhoven. Beste Marcel, graag wil ik 
jou bedanken voor het bewaken van de meer fysisch gerichte aspecten in het enige echte 
technische artikel. Aan het einde waren jouw tips van belangrijke waarde om het artikel 
op voldoende niveau te krijgen.
Anderen die ik graag wil bedanken voor hun bijdrage zijn Wichor Bramer 
(literatuuronderzoeken) en Wilma Bergen Henegouwen. Op de achtergrond kon ik altijd 
op Wilma rekenen als er faciliteiten nodig waren. Dr. Euan Tovey (The University of 
Sydney) en dr. Wolfgang Viechtbauer (Maastricht University) wil ik graag bedanken voor 
hun tips en hulp bij het uitwerken van hoofdstuk vier. Ravebo B.V. te Brielle maakte de 
metingen uit hoofdstuk zeven mogelijk. 
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Waar het hierna om gaat is dat er degelijk vervolgonderzoek van de grond komt, leidend 
tot betrouwbare uitkomsten en duidelijkheid voor de allergische patiënt. Ik hoop hiertoe 
met jullie allen in de toekomst nog meerdere artikelen te mogen schrijven.
Tot slot. Lieve Lanie en Rodney, de afgelopen jaren kostte het schrijven van dit proefschrift 
soms veel privé-tijd. Dank voor jullie steun en begrip! En Lanie ook nog voor haar 
accurate hulp bij de data-extracties!
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A N N E X TO C HA P T E R 2
Reference search; keywords for embase.com
 (‘Pyroglyphidae’/exp OR ‘mite’/de OR ‘Acari’/de OR ‘house dust’/de OR ‘house dust 
allergen’/de OR ‘mite infestation’/de OR ‘house dust allergy’/de OR ‘dust exposure’/de 
OR (Dermatophagoid* OR mite OR mites OR ‘D farinae’ OR ‘d pteronyssinus’ OR 
Pyroglyphid* OR Euroglyph* OR ‘e maynei’ OR Acari* OR housedust* OR (dust NEAR/6 
(allerg* OR sensiti* OR hypersensiti* OR indoor* OR house* OR domestic* OR asthma* 
OR ambient*))):ab,ti) AND (‘air conditioning’/de OR ‘exposure’/de OR ‘dust exposure’/
de OR ‘environmental exposure’/de OR ‘environmental parameters’/de OR ‘avoidance 
behavior’/de OR ‘environmental factor’/de OR ‘environmental management’/de OR 
‘textile’/de OR ‘home environment’/de OR ‘tertiary prevention’/de OR ‘microclimate’/de 
OR ‘room ventilation’/de OR ‘air quality’/de OR ‘ambient air’/de OR ‘air quality control’/
de OR humidity/de OR ‘environmental sanitation’/de OR ‘sanitation’/de OR (avoidance* 
OR (impermeab* NEAR/3 cover*) OR ((humid* OR allergen* OR climate*) NEAR/3 
(control* OR reduction*)) OR (air NEAR/3 (condition* OR filt* OR qualit* OR ambient* 
OR control* OR clean*)) OR ventilat* OR expos* OR textile* OR load OR environment* 
OR (dust NEAR/3 level*) OR anti-mite OR spray* OR mattress* OR management* OR 
(tertiary NEAR/3 prevent*) OR microclimate* OR micro-climate* OR sanitation OR 
bed-cloth* OR bed-cover* OR bedding OR furnish*):ab,ti) AND (‘Controlled clinical 
trial’/exp OR ‘Crossover procedure’/de OR ‘Double-blind procedure’/de OR ‘Single-blind 
procedure’/de OR (random* OR factorial* OR crossover* OR (cross NEXT/1 over*) OR 
placebo* OR ((doubl* OR singl*) NEXT/1 blind*) OR assign* OR allocat* OR volunteer* 
OR trial OR groups):ab,ti) NOT ([animals]/lim NOT [humans]/lim) NOT ([Conference 
Abstract]/lim) AND [English]/lim
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List of included and excluded studies in the updated search
Author Year Included? Rationale
1 Eick 2011 No not patients with house dust mite-allergic asthma
2 Glasgow 2011 No excluded by Gotzsche and Johansen
3 Maas 2011 No not tertiary prevention
4 Neymayr 2011 No not a clinical trial
5 Takaro 2011 No not randomized
6 Breysse 2012 No not a clinical trial
7 Celano 2012 No not patients with house dust mite-allergic asthma
8 El-Ghitany 2012 Yes
9 Gehring 2012 No not tertiary prevention
10 Ho 2012 No abstract
11 Masna 2012 No abstract
12 Scott 2012 No not tertiary prevention
13 NCT 2013 No protocol issue
14 Tsurikisawa 2013 No not blinded
15 Hogaard 2014 No abstract
16 NCT 2014 No duplicate
17 Hogaard 2014 No duplicate
18 Murray 2015 No duplicate
19 Smith 2015 No not blinded
20 Sumner 2015 No duplicate
21 Dimango 2016 No not patients with house dust mite-allergic asthma
22 NCT 2016 No protocol issue
23 Tsurikisawa 2016 No not blinded
24 Winn 2016 No not a clinical trial
25 Luo 2017 No abstract
26 Murray 2017 Yes
27 Morten 2018 No not patients with house dust mite-allergic asthma
28 Bjermer 2019 No not a clinical trial
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Number of trials available per subgroup
Category FEV1 %pred. PC20 Std. ASSs
Steroids 9 9 7
No steroids 5 5 4
Child 5 6 5
Adult 11 9 7
Co-sensitization 8 9 7
No co-sensitization 2 2 2
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Figure A1. Scatterplot for the PC20 against the mite allergen load from the mattress at baseline.
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Figure A3. Scatterplot for the FEV1 percentage of predicted against the mite allergen load from the mattress at baseline.
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Figure A2. Scatterplot for the standardized asthma symptom scores against the mite allergen load from the mattress
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A N N E X TO C HA P T E R 5
Table. Excluded twenty-nine full-text studies for not meeting our inclusion criteria.
First author Year Rationale for exclusion
Villaveces 1977 Incomplete data.
Kooistra 1978 Treatment of rhinitis.
Reisman 1990 Treatment of rhinitis (n = 21) or asthma (n = 11).
Warner 2000 Not the strategy of air purification.
Htut 2001 Not the use of a HEPA filter.
Francis 2003 Not blinded.
Swartz 2004 Not a RCT.
Eggleston 2005 Control received the intervention at the end of the study.
Nct 2005 Not a RCT.
Nct 2005 Not a RCT.
Thomson 2005 Not a RCT.
Wright 2008 Abstract.
Wright 2009 Not the strategy of air purification.
Stillerman 2010 Treatment of rhinitis.
Moffatt 2011 Abstract.
Mohan 2011 Abstract.
Takaro 2011 Not a RCT.
Ho 2012 Abstract.
Yunus 2012 Abstract.
Hogaard 2014 Abstract.
Nct 2014 Not a RCT.
Nct 2014 Not a RCT.
Hogaard 2014 Abstract.
Gore 2015 Not a RCT.
Vijayan 2016 Not a RCT.
Storrar 2016 Not a RCT.
Luo 2017 Abstract.
Miyoshi 2018 Abstract.
Bjermer 2019 Not a RCT (post-hoc analysis).
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